International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

Pertti Panula, Paul L. Chazot, Marlon Cowart, Ralf Gutzmer, Rob Leurs, Wai L. S. Liu, Holger Stark, Robin L. Thurmond, and Helmut L. Haas

Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry (H.S.) and Institute of Neurophysiology, Medical Faculty (H.L.H.), Heinrich-Heine-University Duesseldorf, Germany; and Janssen Research & Development, LLC, San Diego, California (R.L.T.)

Abstract ....................................................................................602
I. Introduction and Historical Perspective .....................................................602
II. Histamine H1 Receptor ........................................................................604
   A. Receptor Structure ........................................................................604
   B. Signal Mechanisms ........................................................................605
   C. Anatomic Framework .....................................................................608
   D. Function .......................................................................................609
   E. H1-Selective Ligands .......................................................................610
   F. Clinical Pharmacology ....................................................................612
III. Histamine H2 Receptor ........................................................................613
   A. Receptor Structure ........................................................................613
   B. Signal Transduction Mechanisms .....................................................614
   C. Anatomic Framework .....................................................................615
   D. Function .......................................................................................616
   E. H2 Receptor-Selective Ligands ...........................................................616
   F. Clinical Pharmacology ....................................................................618
IV. Histamine H3 Receptor ........................................................................619
   A. Receptor Structure ........................................................................619
   B. Signal Transduction Mechanisms .....................................................622
   C. Anatomic Framework .....................................................................623
   D. Function .......................................................................................625
   E. H3-Selective Ligands .......................................................................627
      1. Agonists ..............................................................................627
      2. Antagonists .........................................................................627
   F. Clinical Pharmacology ....................................................................629

P.P. received financial support from The Academy of Finland, The Sigrid Juselius Foundation, The Finnish Foundation for Alcohol Studies and (previously) a lecture compensation from Abbot Laboratories. P.C. received financial support from Gedeon Richter and GSK, compensation from Abbott Laboratories for a lecture and consultancy support from Ziarco Pharma Ltd. M.C. is an employee of AbbVie. R.G. received support from DFG [German Research Foundation GU434/6-1] and project support by Johnson & Johnson. R.L. received financial support from the Netherlands Organisation for Scientific Research (NWO), Abbott Laboratories, Pfizer, and UCB Pharma, and is a founder of Griffin Discoveries. W.L.S.L. is a founder of Ziarco Pharma Limited. R.L.T. is an employee of Janssen Research & Development. H.S. is one of the inventors of pitolisant. NC-IUPHAR is supported in part by Wellcome Trust Grant 099156/Z/12/Z. Original work by P.P., P.C., R.G., R.L., and H.S. was supported by European Cooperation in Science and Technology Action BM0806.

This review is dedicated to the memory of Professor Sir James Black, FRS, Nobel laureate, who died on 22 March 2010, and Professor Walter Schunack, who died on 6 April 2011.

Address correspondence to: Helmut Haas, Institute of Neurophysiology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany. E-mail: haas@uni-duesseldorf.de; or Pertti Panula, Institute of Biomedicine, Anatomy, and Neuroscience Center, University of Helsinki, Finland. E-mail: pertti.panula@helsinki.fi dx.doi.org/10.1124/pr.114.010249.
I. Introduction and Historical Perspective

Histamine pharmacology has experienced a renaissance over the last few decades, with the identification and cloning of the histamine H₃ and H₄ receptors, which doubles the members of the histamine receptor family. This has led to a massive increase in our understanding of the histamine systems in the whole body and recently resulted in the introduction of H₃ receptor and H₄ receptor drug leads into late-stage clinical development, with an ever expanding range of potential therapeutic applications. The molecular identification of the H₃ receptor and H₄ receptor, their attendant isoforms, and species variants have now clarified to some degree the pharmacological heterogeneity reported in the 1990s, reviewed in the previous Pharmacological Reviews article by Hill et al. (1997). This present review is dedicated to two of the foremost histamine receptor pharmacologists, Sir James Black and Walter Schunack, who sadly died at the beginning of 2010 and 2011, respectively. They provided the field with prototypical compounds and drugs, particularly in the H₂ receptor and H₃ receptor fields and contributed profoundly to our current understanding of histamine pharmacology.

Histamine (1) is an endogenous biogenic amine distributed ubiquitously in the body being present in high concentrations in the lungs, skin, and gastrointestinal tract (Fig. 1). Histamine is synthesized and stored at high concentrations within granules in so called "professional" cells, basophils and mast cells, where it is associated with heparin. Based on a sensitive high-performance liquid chromatography-mass spectrometry method, nonmast cell histamine occurs at high concentrations in enterochromaffin-like cells in the stomach, lymph nodes, and thymus, with modest levels in the liver, lung, and in varicosities of the histaminergic neurons in the brain (Zimmermann et al., 2011). Histamine acts as a neurotransmitter in the nervous system and as a local mediator in the gut, skin, and immune system. Histamine brings about complex physiologic changes, including neurotransmission, inflammation, smooth muscle contraction, dilatation of capillaries, chemotaxis, cytokine production, and gastric acid secretion. These biologic changes occur via four G protein–coupled receptor (GPCR) subtypes: H₁ receptor, H₂ receptor, H₃ receptor, and H₄ receptor. These seven-transmembrane domain GPCR proteins represent the largest family of membrane proteins in

### ABBREVIATIONS:
- bp, base pair
- CNS, central nervous system
- EAE, experimental autoimmune encephalitis
- ECL, extracellular loop
- ERK, extracellular signal-regulated kinase
- GPCR, G protein–coupled receptor
- HDC, histidine decarboxylase
- IFN, interferon
- IL, interleukin
- IPSP, inhibitory postsynaptic potential
- KO, knockout
- LPS, lipopolysaccharide
- MAPK, mitogen-activated protein kinase
- NAADP, nicotinic acid dinucleotide phosphate
- NMDA, N-methyl-D-aspartate
- NO, nitric oxide
- PBMC, peripheral blood mononuclear cells
- PET, positron emission tomography
- PRA, protein kinase A
- PKC, protein kinase C
- PLC, phospholipase C
- SAR, structure-activity relationship
- TLR, Toll-like receptor
- TM, transmembrane
- TNFα, tumor necrosis factor α
the human genome (Jacoby et al., 2006; Lagerstrom and Schioth, 2008) and have proven to be one of the most rewarding families of drug targets to date. All members, including the histamine receptors, share a common membrane topology, comprising an extracellular N terminus, an intracellular C terminus, and seven transmembrane (TM) helices interconnected by three intracellular loops and three extracellular loops. The relative concentrations of histamine required to activate respective histamine receptor subtypes are different. For example, H₁ receptors and H₂ receptors have relatively low affinity for histamine in comparison with H₃ receptors and H₄ receptors, thus the local concentrations of histamine and the presence of different receptor subtypes adds specificity to histamine responses.

The classification of the histamine receptor family was historically based on pharmacological definitions but has subsequently relied upon the molecular biologic identification of new histamine receptor genes and the elucidation of four distinct histamine receptor polypeptide sequences. However, apparent molecular heterogeneity, through alternative splicing, has increased the number of potential receptor isoforms, particularly with the rat and human H₃ receptor. This heterogeneity will be discussed in detail within this review. Moreover, with the availability of recombinant expression systems, new phenomena, including constitutive histamine receptor signaling and receptor oligomerization, have been shown for almost all of the histamine receptor subtypes (see next sections).

Constitutive GPCR activity is recognized for many GPCR family members and results in GPCR signaling without the need of an external agonist (Smit et al., 2007). This spontaneous GPCR signaling is thought to evolve from the conformational dynamics of GPCR proteins, resulting in equilibria between active and inactive receptor states. These equilibria can be altered by GPCR mutations, such as, e.g., in some inherited diseases (Smit et al., 2007), and by GPCR ligands. Agonists drive the equilibria toward active GPCR conformation(s), whereas so-called inverse agonists would favor the inactive conformations. Following this notion, many of the known GPCR antagonists (including the histamine receptor antagonists) have been reclassified as inverse agonists (Smit et al., 2007), whereas true (neutral) antagonists are difficult to identify for most GPCRs.

Oligomerization occurs in most if not all GPCRs, including several of the histamine receptor subtypes (see sections below). However, it is not clear whether this occurs in vivo in all cases and what might be the functional significance of this (Vischer et al., 2011). The majority of the studies have been performed with in vitro heterologous systems with recombinant receptors [e.g., H₄ receptor (van Rijn et al., 2006)]. However, there is growing in vivo evidence for oligomerization for some classes of GPCRs, including class C GPCRs, for example, GABA<sub>δ</sub> and metabotropic glutamate receptors. Structures comprising monomers, dimers, and higher-order oligomers of GPCRs have been shown to assemble into transient and/or stable homo-oligomeric and hetero-oligomeric macromolecular complexes. It is unclear whether the individual protomers within a homodimeric structure are always equivalent or play distinct roles in agonist occupancy and/or G protein activation, as appears to be the case in class C GPCRs.

The current status of the field was recently nicely reviewed (Ferre et al., 2014). The increased molecular understanding of the histamine receptor proteins has been paralleled by developments in the field of histamine receptor pharmacology. The first histamine receptor antagonist drugs were developed in the 1930s and 1950s, over 20 years after their discovery in 1910 (Simons and Simons, 2011). The H₂ receptor was discovered in the early 1970s (Powell and Brody, 1976) and the H₃ receptor in the early 1980s (Arrang et al., 1983), and finally, the last member to join the group, the H₄ receptor, was identified using molecular biologic techniques at the beginning of the millennium (Nakamura et al., 2000; Liu et al., 2001a; Morse et al., 2001; Nguyen et al., 2001; Zhu et al., 2001; O’Reilly et al., 2002).

The first two receptors have been exploited extremely successfully in the development of a range of “blockbuster” drugs. There is now growing anticipation that the two most recently discovered histamine receptor subtypes will yield further therapeutic success, because ligands for both recently entered clinical development, with the H₃ receptor antagonist, pitolisant (Wakix) being filed for licensing by Bioprojet (Paris, France) in May 2014. The field waits to see if this filing is successful. In a similar fashion, although some positive results have been reported for H₄ receptor ligands in early clinical trials, the first H₄ receptor drug is yet to be filed and registered.

Gene-targeted histidine decarboxylase (HDC) knock-out (KO) mice have provided a large amount of information regarding the role of histamine. These mice are viable, fertile, and display no gross abnormalities except for abnormal mast cells (Ohtsu et al., 2001). However, there are permanent changes in the cortical-electroencephalogram and sleep-wake cycle: At moments when high vigilance is required, mice lacking brain histamine are unable to remain awake, a
prerequisite condition for responding to behavioral and
cognitive challenges (Parmentier et al., 2002), changes
in learning ability (Dere et al., 2003), and increased
obesity in high-fat diet–fed mice (Haas et al., 2008).

The combinatorial roles of all four histamine
receptors were studied in autoinflammatory disease
of the nervous system in the search of an effective
therapy for multiple sclerosis. H1 receptor, H2 receptor–
of the nervous system in the search of an effective
receptors were studied in autoinflammatory disease
approaches, there is strong evidence that the H1 receptor
fluorescence resonance transfer and mutagenesis
(Garcia-Martin et al., 2009; Micallef et al., 2013). Teuscher’s
group (Saligrama et al., 2013) also compared the
phenotypes of H1,2,3,4 receptor- and HDC-knockout
mice; unexpectedly and interestingly they displayed
opposite phenotypes.

This review will focus on the advances in our
understanding of histamine pharmacology that have
occurred since the last review published in 1997 (Hill
et al., 1997). Histamine receptors can be accessed
through the International Union of Basic and Clinical
Pharmacology/British Pharmacological Society Guide
to Pharmacology (Alexander et al., 2013; http://www.
guidetopharmacology.org/GRAC/FamilyDisplayForward?
familyId=33).

II. Histamine H1 Receptor

The first histamine receptor has been known since its
pharmacological characterization using antagonists
(Bovet and Staub, 1937) and agonists (Black et al.,
1972). It was identified as a glycoprotein (Garbarg et al.,
1985) and cloned in 1991 (Yamashita et al., 1991). It is
very widely expressed throughout the body in epithelial,
vascular, smooth vascular, neuronal, glial, and immune
cells (Hill et al., 1997; Haas et al., 2008; Shimamura
et al., 2011). This receptor is responsible for the early
biologic method to determine histamine by contraction
of guinea pig ileum preparations and most of the
symptoms caused by histamine in allergy and asthma,
except the inflammatory component.

A. Receptor Structure

As all four histamine receptors, the H1 receptor
belongs to the GPCR family. The bovine H1 receptor
cDNA was cloned in 1991 by expression cloning in the
classic Xenopus oocyte system (Yamashita et al., 1991).
This led rapidly to the cloning of the receptor cDNA in
several species, including human in 1993 and 1994 (De
Backer et al., 1993; Moguilevsky et al., 1994). The
human gene was subsequently localized to chromo-
some 3p14-p21 (Le Coniat et al., 1994). A single H1
receptor polymorphism rs7651620 Glu270Gly has been
identified that is relevant to African subjects only
(Garcia-Martin et al., 2009; Micallef et al., 2013).

On the basis of immunoprecipitation, time-resolved
fluorescence resonance transfer and mutagenesis
approaches, there is strong evidence that the H1 receptor
is expressed as both homomeric and oligomeric struc-
tures. Furthermore, evidence has been provided for the
presence of robust domain-swapped H1 receptor dimers
in which there is a reciprocal exchange of TM6 and 7
between the individual monomers in the dimer (Bakker,
2004).

Structural biology in GPCRs recently received
tremendous input with the solved crystal structures
of numerous GPCR family members, including many
biogenic amine receptors (for a complete list, see, e.g.,
http://www.gpcr.org/7tm/ or http://zhanglab.cchem.med.
umich.edu/GPCRSD/). In 2011, the 3.1 Å resolution
structure of a stabilized mutant human H1 receptor in
complex with the first generation H1 receptor antago-
nist doxepin was reported (Shimamura et al., 2011).
Crystallization was made possible by a replacement of
the large third intracellular loop with T4-lysozyme
fusion protein (H1 receptor-T4L) and numerous other
technical advances. Doxepin stabilizes the H1 receptor
in an inactive (R) state by preventing movements in the
so-called ‘‘toggle switch” in TM6, an element proposed to be important in activation in many GPCRs.
Obviously, on the basis of phylogenetic relationships,
the H1 receptor shares more structural similarities
with the other aminergic receptors than with the more
distant GPCRs. Some common motifs in the TM region
can be recognized [TM3: D(ER)Y; TM6: CWxP; TM7:
NPxxY], as well as a disulfide bond that connects the
long extracellular loop 2 (ECL2) with the extracellular
end of TM3 (Shimamura et al., 2011). Interestingly, the
palmitoylation site at the end of TM7, which has often
been recognized as a membrane anchor, is missing in
H1 receptor (Fig. 2).

The binding pocket of doxepin involves the highly
conserved Asp1073.32 in TM3 and aromatic residues in
TM5 and 6 (e.g., Phe4246.44, Trp4286.48, and
Phe4326.52 (Shimamura et al., 2011)), as previously had
been assumed for related H1 receptor antagonists
based on site-directed mutagenesis and homology
modeling exercises (Ohta et al., 1994; Nonaka et al.,
1998; Wieland et al., 1999). The strong hydrophobic
interactions of the aromatic moieties of doxepin
with Trp4286.48 may prevent movement of helix 6, which
is generally seen as one of the hallmarks of GPCR
activation. Doxepin binds relatively deep in the
binding pocket defined by TM3, -5, and -6. Interest-
antly, in the X-ray structure an additional phosphate-
binding pocket defined at the entrance of the ligand-binding
 pocket is observed as a novel feature. The phosphate
anion is coordinated by Lys179ECL2, Lys1915.39, and
His4507.35, and this binding pocket is suggested to play
a role in the interaction with the second generation
zwitterionic antihistamines (Shimamura et al., 2011).
Evidence for a role of Lys1915.39 and extracellular
domains of the H1 receptor in ligand–receptor inter-
actions has earlier been obtained by mutagenesis and
molecular dynamics studies (Wieland et al., 1999;
Insights into the molecular features governing agonist-induced H₁ receptor activation await the resolution of an active H₁ receptor X-ray structure and currently still rely on molecular modeling and/or mutagenesis studies (Ohta et al., 1994; Jongejan et al., 2005; Strasser et al., 2008b; Sansuk et al., 2011). Histamine is thought to bind the H₁ receptor with its protonated ethylamine side chain via Asp1073.32 (Ohta et al., 1994), whereas the imidazole ring is thought to interact with Asn198 5.46 and Lys1915.39 (Leurs et al., 1994a, 1995a). The interaction of the protonated side chain with Asp1073.32 allows potentially for the release of Ser3.36, allowing it to act as a toggle switch and to interact with Asn7.45 in the active state of the receptor (Jongejan et al., 2005) (Fig. 3; Table 1).

B. Signal Mechanisms

The human H₁ receptor produces its action mainly by coupling to Gᵣ/₁₁ proteins (Gutowski et al., 1991; Leopoldt et al., 1997; Selbach et al., 1997; Moniri et al., 2004), but also signals via Gᵣ₀ in some systems (Seifert et al., 1994; Wang and Kotlikoff, 2000), and the small G protein family, most likely through an indirect downstream effect (Mitchell and Mayeenuddin, 1998). Direct interaction of the H₁ receptor with Gᵣ/₁₁ was recently visualized in real time in HELA cells endogenously expressing H₁ receptor (Adjobo-Hermans et al., 2011).

The major signaling pathway for H₁ receptor elicits activation of phospholipase C, which produces 1,2-diacylglycerol and inositol-1,4,5-trisphosphate, leading to activation of protein kinase C (PKC), catalyzing the Ser/Thr phosphorylation of multiple downstream mediators and release of calcium ions from intracellular stores, respectively (Hill et al., 1997). This leads to calcium ion entry through calcium channels, cation channels of the transient receptor potential channel type (Brown et al., 2002; Doreulee et al., 2003), and stimulation of a Na⁺/Ca²⁺ exchanger (Eriksson et al., 2001; Sergeeva et al., 2003). Nicotinic acid adenine dinucleotide phosphate (NAADP) has also been suggested as a potential second messenger in histamine-induced Ca²⁺ release from lysosome-like acidic compartments, functionally coupled to the endoplasmic reticulum via H₁ receptor in endothelial cells. By using the human EA.hy926 endothelial cell line and primary human umbilical vein endothelial cells, selective H₁ receptor activation increases intracellular NAADP levels, and Ca²⁺ release was shown to involve both acidic organelles and the endoplasmic reticulum. Furthermore, H₁ receptor-induced von Willebrand factor secretion has been shown to require a specific Ca²⁺ signaling and NAADP mechanism (Esposito et al., 2011) (Fig. 4).

H₁ receptors also mediate the production of arachidonic acid, nitric oxide, and cyclic GMP (Richelson, 1978; Snider et al., 1984; Leurs et al., 1994b; Prast and Philippu, 2001) through Gᵣ/Gᵣ₀ protein–mediated activation of phospholipase A₂, [Ca²⁺]ᵢ-dependent nitric oxide (NO) synthases, and NO-dependent guanyl cyclases, respectively. NO is thought to be involved in the histamine-induced suppression of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolopropionic acid) receptor-mediated synaptic currents in supraoptic neurons through activation of H₁ receptor. Histamine is believed to act initially at supraoptic cells (perhaps both neuronal and non-neuronal) to induce the production of NO, which then locally modulates synaptic transmission via a postsynaptic mechanism (Li and Hatton, 2000). Stimulation of the H₁ receptor also increases endothelial NO synthase transcription in human vascular endothelial...
cells via a Ca\(^{2+}\)/calmodulin-dependent protein kinase II (CaMKII) signaling pathway, which may be protective under normal conditions, but in contrast, may be deleterious under conditions of oxidative stress, when endothelial NO synthase can produce reactive oxygen species at the expense of NO (Li et al., 2003). Histamine, through H\(_1\) receptors, increases endothelial NO production as an endothelium-dependent vasodilator but acts as a vasoconstrictor in atherosclerotic coronary arteries.

In the mammalian brain, adrenal glands, and CHO cells, activation of the H\(_1\) receptor also stimulates

---

**TABLE 1**

Overview human histamine receptor subtypes (\(\lambda H_1\) receptor-\(\lambda H_4\) receptor).

<table>
<thead>
<tr>
<th></th>
<th>(\lambda H_1)R</th>
<th>(\lambda H_2)R</th>
<th>(\lambda H_3)R</th>
<th>(\lambda H_4)R</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chromosomal gene location</strong></td>
<td>3q25</td>
<td>5q35.2</td>
<td>20q13.33</td>
<td>18q11.2</td>
</tr>
<tr>
<td><strong>Amino acids</strong></td>
<td>359</td>
<td>445</td>
<td></td>
<td>390</td>
</tr>
<tr>
<td><strong>Isoforms</strong></td>
<td></td>
<td>at least 20 (65, 66)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>G protein coupling</strong></td>
<td>(\alpha_{q/11})</td>
<td>(\alpha_s)</td>
<td>(\alpha_{i/o})</td>
<td>(\alpha_{i/o})</td>
</tr>
<tr>
<td><strong>Constitutive activity</strong></td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td><strong>Signal transduction</strong></td>
<td>PLC(^\dagger), Ca(^{2+})(^\dagger)</td>
<td>cAMP(^\dagger)</td>
<td>cAMP(^\dagger), Ca(^{2+})(^\dagger), MAPK(^\dagger)</td>
<td>cAMP(^\dagger), Ca(^{2+})(^\dagger), MAPK(^\dagger)</td>
</tr>
<tr>
<td><strong>Tissue localizations</strong></td>
<td>Ubiquitous (mainly lung, CNS, blood vessels)</td>
<td>Ubiquitous (mainly stomach, heart, CNS)</td>
<td>Neurons (CNS and PNS)</td>
<td>Bone marrow, hematopoietic cells</td>
</tr>
<tr>
<td><strong>Physiologic relevance</strong></td>
<td>Bronchoconstriction, vasoconstriction, food intake, sleep-wake regulation</td>
<td>Gastric acid secretion</td>
<td>Neurotransmitter release (→ sleep-wake regulation, attention/cognition, food intake)</td>
<td>Immune responses (→ chemotaxis, IL-, IFN-modulation)</td>
</tr>
<tr>
<td><strong>Pathophysiological conditions</strong></td>
<td>Allergic reactions, emesis, sleep-wake disorders</td>
<td>Gastric ulcers</td>
<td>Cognitive impairment, schizophrenia, sleep-wake disorders, epilepsy, pain, etc.</td>
<td>Inflammatory diseases (allergy, asthma, pruritus, arthritis), pain, etc.</td>
</tr>
</tbody>
</table>

* and ++, extent of constitutive activity; PL, phospholipase; PNS, peripheral nervous system.
adenylyl cyclase and consequently cAMP production, the canonical signaling pathway of the H₂ receptor (see below). In rat brain, the cAMP production is dependent upon PKC activation and intra- and extracellular calcium ion levels (Marley et al., 1991). In the adrenal gland, H₁ receptor activation of adenylyl cyclase is dependent on extracellular Ca²⁺ only (Marley et al., 1991). The stimulatory effects of histamine on cAMP production are most likely not mediated directly through Gₐ coupling but rather indirectly via an increase in [Ca²⁺], and the release of activated Gbg-subunits. For example, the neuronally expressed adenylyl cyclase 1 is a paradigm for a Ca²⁺/calmodulin-stimulated adenylyl cyclase (Sunahara and Taussig, 2002).

H₁ receptor activation in transfected CHO cells increases forskolin-dependent cAMP production, which is independent of extracellular Ca²⁺ and PKC activation and is pertussis toxin–insensitive (Leurs et al., 1994b). Stimulation of H₁ receptors activates adenylyl cyclase in CHO cells relies on the release of Gbgγ-subunits from G proteins, thereby elevating intracellular cAMP concentrations (Maruko et al., 2005).

It is well established that histamine modulates cell proliferation through the activation of the H₁ receptor. The H₁ receptor can signal to the nucleus via PKCα subsequent to activation of phospholipase Cβ (Megson et al., 2001). Functional coupling of the H₁ receptor to Gq-phospholipase C (PLC) leads to the activation of RhoA and Rac small GTPases through a direct interaction of activated Gq-subunits with p63RhoGEF and suggest distinct roles for Rho GTPases in the control of cell proliferation by histamine that has relevance in cancer biology (Valencia et al., 2001; Lutz et al., 2007; Notcovich et al., 2010). Moreover, also the canonical β-catenin pathway is activated downstream of the H₁ receptor in a variety of cell types. Stimulation of the H₁ receptor elicits transactivation of a T-cell factor/β-catenin–responsive construct in HeLa cells and in the SW-480 colon cell line. Furthermore, histamine treatment increases phosphorylation of glycogen synthase kinase 3-β in HeLa cells, murine macrophages, and DLD-1, HT-29, and SW-480 colon cell lines, whereas histamine also decreases the phosphorylated β-catenin content in HeLa cells and murine macrophages (Diks et al., 2003).

The H₁ receptor displays constitutive receptor activation in the absence of agonists (Bakker et al., 2000; Jacoby et al., 2006), as measured by, e.g., inositol phosphate production and nuclear factor-kB reporter gene activation. This finding resulted in the reclassification of H₁ receptor ligands; agonists activate the receptor (2–5), inverse agonists inhibit the constitutive activity and neutral antagonists inhibit the actions of both agonists and inverse agonists without modifying constitutive activity. All the “classical” antihistamines are indeed inverse agonists (Bakker et al., 2000) (6–16), while the experimental ligands, histabudifen and histapendifen are neutral antagonists (Govoni et al., 2003). These latter compounds may allow the study of in vivo relevance of H₁ receptor constitutive antagonism, which remains to be elucidated. As with many GPCRs, the extent of H₁ receptor constitutive activity depends on the specific parameter determined (Bakker et al., 2007; Appl et al., 2012). The high
The constitutive activity of the H₁ receptor upon assessment of distal signaling parameters, i.e., reporter gene expression, may be explained by the fact that the concentration of effectors is limiting the cascade so that even a small number of constitutively active H₁ receptor results in a high agonist-dependent signal. In fact, in native systems, there is little evidence to date for high constitutive H₁ receptor activity.

A growing number of studies have also provided evidence for the concept of multiple signaling pathways activated by a single receptor (functional selectivity, biased signaling or ligand-specific receptor conformations) (Moniri and Booth, 2004; Galandrin et al., 2007; Kobilka and Deupi, 2007; Kenakin, 2011; Seifert et al., 2011). One of the first studies to support the concept of agonist-dependent functional selectivity at the H₁ receptor used the two H₁ receptor ligands, (±)-cis-5-phenyl-7-dimethylamino-5,6,7,8-tetrahydro-9H-benzocycloheptane (cis-PAB) and (−)-trans-1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene (trans-PAT) derived from the same chemical class (but with distinct stereochemistry) which were shown to display functional selectivity, the former stimulating cAMP production and the latter, PLC/inositol-1,4,5-trisphosphate metabolism (Moniri et al., 2004). However, as for constitutive H₁ receptor signaling, currently there is no evidence for the importance of biased signaling in vivo.

The H₁ receptor-mediated signaling cascade is known to desensitize quickly (Smit et al., 1992; McCreath et al., 1994) via both PKC-dependent and -independent mechanisms. GPCR kinase 2 is the principal GPCR kinase mediating agonist-induced H₁ receptor desensitization in HEK293 cells (Iwata et al., 2005). The H₁ receptor-mediated signaling, furthermore, can be inhibited by phorbol ester-induced PKC activation. Two amino acid residues (Ser396, Ser398) have been shown to be PKC phosphorylation sites by in vitro phosphorylation studies using a series of synthetic peptides. Moreover, treatment with phorbol ester decreased histamine-induced accumulation of inositol phosphates in CHO cells expressing the H₁ receptor. Site-directed mutagenesis studies showed that Ser398 was the principle residue involved in PKC-mediated desensitization (Fujimoto et al., 1999) (Fig. 5).

C. Anatomic Framework

H₁ receptors are found throughout the whole body and nervous system with considerable variations among species (Chang et al., 1979). H₁ receptors are expressed in vascular and airway smooth muscle, chondrocytes, hepatocytes, endothelial cells, dendritic cells, monocytes, neutrophils, T and B cells (Jutel et al., 2001, 2009; Togias, 2003). The distribution in the brain is uneven, and because of the circuit organization of the central nervous system (CNS), the anatomy is particularly relevant. Some of the early studies on localization and physiologic/pharmacological implications of H₁ receptors, discussed extensively in Hill et al. (1997), are only listed here: blood vessels (Barger and Dale, 1910; Dale and Laidlaw, 1910; Folkow et al., 1948; Black et al., 1972), other smooth muscle preparations (Marshall and Cherry, 1955; Ash and Schild, 1966; Black et al., 1972; Hill, 1990) and heart (Sakuma et al., 1988). The distribution of H₁ receptors in different mammalian tissues was first studied using selective radioligands such as [³H]mepyramine (Hill et al., 1977), later using in situ hybridization (Fig. 5). [¹¹C] Mepyramine (cf. 8) and [¹¹C]doxepin have also proved useful for imaging H₁ receptors in the living human brain (Villemagne et al., 1991; Yanai et al., 1992).

H₁ receptor stimulation leads to endothelial cell contraction and thus increases vascular permeability,

---

**Fig. 5.** Expression and receptor radioligand binding to cross sections of the rat brain. Data are shown for both mRNA distribution from in situ hybridization films and autoradiograms after labeling with radioactive ligands for each receptor. For identification of the brain areas, the following areas are marked in (A–D): 1, retrosplenial granular cortex; 2, primary somatosensory cortex; 3, entorhinal cortex; 4, CA1 area of the hippocampus; 5, dentate gyrus; 6, caudate putamen; 7, amygdala; 8, zona incerta; 9, lateral hypothalamic area; 10, arcuate nucleus; 11, dorsal lateral geniculate nucleus. Modified from Haas and Panula (2003).
and the release of several bioactive substances including nitric oxide. H\textsubscript{1} receptors also modulate the action of chromaffin cells in the adrenal medulla and lymphocytes (see Hill et al., 1997). An autoimmune disease locus, Bphs has been identified as H\textsubscript{1} receptor (Ma et al., 2002). Endothelial H\textsubscript{2} receptor signaling reduces blood-brain barrier permeability and susceptibility to autoimmune encephalomyelitis (Saligrama et al., 2012).

H\textsubscript{1} receptors are widely distributed in mammalian brain (Hill, 1990; Schwartz et al., 1991). Particularly high densities are found in brain regions concerned with neuroendocrine, behavioral, and nutritional state control, including the periventricular, suprachiasmatic, and ventromedial nuclei of the hypothalamus, aminergetic and cholinergic brainstem nuclei, thalamus, and cortex (Schwartz et al., 1991). In human brain, the highest \[^{[3]}\text{H}\]mepyramine binding is found in the cerebral cortex and the infralimbic structures (Martinez-Mir et al., 1990), in keeping with the mapping of the H\textsubscript{1} receptor using \[^{[125]}\text{I}\]iodobolpyramine autoradiography in the guinea pig (Bouthenet et al., 1988). The distributions in rat (Palacios et al., 1981a) and guinea pig (Palacios et al., 1981b) are similar to each other and to humans with some exceptions: the guinea pig cerebellum shows high density (Chang et al., 1979; Hill and Young, 1980; Bouthenet et al., 1988; Ruat and Schwartz, 1989) in contrast to the low density in the rat, and the rat thalamus shows a clearly lower H\textsubscript{1} receptor mRNA expression than the guinea pig (Lintunen et al., 1998). In most brain areas, there is overlap of H\textsubscript{1} receptor binding sites and messenger ribonucleic acid levels except in hippocampus, where the pyramidal cell layer shows high mRNA expression and molecular layer high radioligand binding (Lintunen et al., 1998), and cerebellum in which the discrepancy is likely to reflect the presence of abundant H\textsubscript{1} receptors in dendrites of pyramidal and Purkinje cells, respectively (Traiffort et al., 1994). In the hippocampus, both the H\textsubscript{1} receptor mRNA expression and radioligand binding sites are in clear contrast with the low density of histamine-containing nerve fibers (Lintunen et al., 1998), which suggests that the turnover of histamine in hippocampus is rapid. Figure 5 shows the distribution of H\textsubscript{1} receptor mRNA in the rat brain at midhypothalamic level in comparison with corresponding H\textsubscript{2} receptor radioligand binding profiles. These patterns are also shown in comparison for H\textsubscript{2} receptors and H\textsubscript{3} receptors. Kainic acid-induced limbic seizures rapidly upregulate H\textsubscript{1} receptor mRNA expression in the rat caudate, putamen, and granular layer of the dentate gyrus (Lintunen et al., 1998). This effect is in line with the findings on the protective role of histamine through H\textsubscript{1} receptor versus kainic acid induced hippocampal damage (Kukko-Lukjanov et al., 2006). In immature mice, H\textsubscript{1} receptor activation also plays a pivotal role in regulation of seizure intensity and duration, and seizure-induced neuronal damage (Kukko-Lukjanov et al., 2010).

In human brain, higher densities of H\textsubscript{1} receptor radioligand binding sites are found in neocortex, hippocampus, nucleus accumbens, thalamus, and posterior hypothalamus, whereas cerebellum and basal ganglia show lower densities (Chang et al., 1979; Kanba and Richelson, 1984; Martinez-Mir et al., 1990; Villemagne et al., 1991; Yanai et al., 1992). In human prefrontal cortex, the highest mRNA expression is found in deep layers IV, V and VI, with slightly higher levels in layer V than the other layers in most areas (Jin and Panula, 2005). The \[^{[3]}\text{H}\]mepyramine binding levels is highest in layer III of the prefrontal cortex, suggesting that the apical dendrites of neurons in the deep laminae contain H\textsubscript{1} receptors (Jin and Panula, 2005). In human thalamus, the anterior, medial, central and lateral nuclear region in dorsal and medial parts of the thalamus show higher H\textsubscript{1} receptor mRNA expression than posterior and ventral parts (Jin et al., 2002). Although \[^{[3]}\text{H}\]mepyramine is also detectable throughout thalamic nuclei, it is modest and many of the H\textsubscript{1} receptor expressing neurons are likely to project to the cerebral cortex (Jin et al., 2002). With availability of appropriate positron emission tomography (PET) tracers \([^{[13]}\text{C}]\text{pyrilamine and }^{[13]}\text{C}]\text{doxepin}) in the early 90s (Yanai et al., 1992), H\textsubscript{1} receptor distribution and occupancy in humans have also been mapped using functional imaging techniques (Yanai and Tashiro, 2007) to study the sedative properties and blood-brain barrier permeability of H\textsubscript{1} receptor antagonists (Tashiro and Yanai, 2007), aging (Yanai et al., 1992), and neuropsychiatric disorders, such as Alzheimer’s disease, schizophrenia (Iwabuchi et al., 2005), and depression (Kano et al., 2004), in all of which H\textsubscript{1} receptor binding was found to be lower than in age-matched healthy controls (Fig. 6).

D. Function

Calcium ion influx leads to depolarization and contraction of smooth muscle cells. This is a classic experimental pharmacological setting used in teaching and research. For example, in guinea pig ileum smooth muscle preparations, H\textsubscript{1} receptor antagonists concentration-dependently inhibit histamine-induced contraction, which offers a simple and quantitative ex vivo testing system for H\textsubscript{1} receptor ligands. Guinea pig trachea and rat aortic rings offer further smooth muscle preparations frequently used in pharmacological assay systems. Following the cloning of the H\textsubscript{1} receptor, it became possible to express the receptor in heterologous systems and measure [Ca\textsuperscript{2+}] levels or inositol phosphate hydrolysis directly in vitro. This has enabled further advances in understanding of H\textsubscript{1} receptor signaling. Using transfected cells, it was shown that via both G\textsubscript{a_q11}- and G\textsubscript{b\gamma}-subunits human H\textsubscript{1} receptors can activate nuclear factor-\textsc{κ}B, a transcription factor prominent in inflammation (Bakker et al., 2001).

H\textsubscript{1} receptor activation excites neurons in most brain regions, including brain stem (Lin et al., 1996; Barbara et al., 2002; Korotкова et al., 2005), hypothalamus
variants in Tourette syndrome families indicated a strong association with histaminergic signaling, particularly within H1 receptor pathways (Fernandez et al., 2012).

**E. H1-Selective Ligands**

Despite the fact that histamine regulates numerous physiologic and pathophysiological effects via H1 receptors, the research area of the corresponding agonistic active compounds has been neglected for a long time. Modifications of the endogenous ligand led to 2-(thiazol-2-yl)ethanamine (2) and later to 2-(3-bromophenyl) histamine or 2-(3-(trifluoromethyl)phenyl)histamine (3) (Fig. 7). Although the well characterized 2-(thiazol-2-yl)ethanamine shows only a moderate efficacy of about 26% of that of histamine with a partial agonist behavior, it clearly demonstrated that the tautomeric shift on the imidazole nitrogen atoms is not an essential structural element. Also with other nonimidazole heterocyclic compounds such as the ergot derivative lisuride (partial) agonist properties intrinsic activity from 0.27 to 1.0 (intrinsic activity of histamine = 1.0) could be observed (Bakker et al., 2004b; Pertz et al., 2004). 2-Phenylhistamines were initially developed as H1 receptor ligands. However, a recent study revealed that the histamine receptor subtype is selectivity strongly affected by N-substitution. In contrast to the corresponding primary amines, the N-methylated phenylhistamines (KK62) have significantly higher affinity for the H4 receptor than the H1 receptor (Strasser et al., 2009; Wittmann et al., 2011a). Compounds with higher maximal efficacies than that of histamine could be obtained by histamine substitution in the 2-position by a diphenylpropyl moiety. This class of histaprodifens is supposed to simultaneously occupy an agonist as well as an antagonist binding site as shown by site-directed mutagenesis studies and molecular modeling techniques (Bruysters et al., 2007), showing slight improvement in efficacy from histaprodien (4) over methylhistaprodien to suprahistaprodien (5) (Jongejan and Leurs, 2005). The distance of three methylene groups between the diphenyl structure and the imidazole ring seems to be crucial as shorter chains led to partial agonists and longer alkyl bridges to antagonists. Phenoprodifens, combining a phenylhistamine and histaprodien partial structure represent a new class of H1 receptor partial agonists/neutral antagonists (Strasser et al., 2008a) (Fig. 7).

The relatively low number of H1 receptor agonists is in contrast to the high number of different H1 receptor antagonists. Pharmacologically, they are divided into different generations because of their target profile and their unwanted side effects. Most of these compounds, if not all of them, are now pharmacologically more clearly defined as inverse agonists (Bakker et al., 2007), with the extent of inverse agonism being parameter dependent. The first generation “antihistamines”

---

**Fig. 6.** Excitation of rat brainstem neurons by histamine through H1 receptor activation. (A) Inward current in a dorsal raphe neuron with increase in channel noise indicating (transient receptor potential channel-type) channel openings. (B) Increase in firing rate of 15 GABAergic (averaged) neurons in the substantia nigra (modified from Brown et al., 2002, and Korotkova et al., 2002).
are structurally described as two aromatic elements linked through a mainly three membered bridge to a basic aliphatic tertiary amino functionality. Diphenhydramine (6), doxylamine (7), mepyramine (pyrilamine; 8), doxepine, dimetinden (9), and bamipine are a few examples based on this general construction pattern. These compounds have in common that they easily cross the blood-brain barrier causing sedation (Nicholson et al., 1991) and/or anticholinergic effects (Hill, 1990). At higher dosages, numerous examples of these compounds also display anesthetic effects that may have some therapeutic advantages on topical applications for urticaria or itch (Orhan et al., 2007; Murota and Katayama, 2011). However, it should also be noted that at high concentrations, first-generation \( H_1 \) receptor antagonists, because of their cationic-amphiphilic properties, can also exhibit paradoxical proinflammatory effects that are mediated via a direct and receptor-independent activation of \( G_i \) proteins in cells of the immune system (Burde et al., 1996).

The class of (polycyclic) neuroleptics has been developed out of the lead structure of early \( H_1 \) receptor antagonists. Therefore, it is not surprising that many of the neuroleptics still possess high \( H_1 \) receptor antagonist affinities, causing sedation and weight gain. One may also assume that the antidepressants acting as selective inhibitors of neurotransmitter transporters have been detected by variation of the \( H_1 \) receptor antagonist lead structure (e.g., diphenhydramine [6] versus fluoxetine), leading to a different pharmacological profile. It is clear that the members of family A of rhodopsin-like GPCRs share some sequence homology and therefore have comparable recognition areas for some structural motifs. These recurrently revealed fragments are termed privileged structures. The privileged structures can be detected in many compounds targeting the biogenic amine receptors in different combinations for receptor preference. With the \( H_3 \) receptor, it is the diaryl element that may be incorporated in a tricyclic

---

**Fig. 7.** \( H_1 \) receptor ligands.
H1 receptors mostly for marketed compounds only. By fulfilling all these requirements, the highly potent mepyramine (also called pyrilamine [8]) has often been used as reference antagonist and for radiolabeling studies (Tashiro and Yanai, 2007; Yanai and Tashiro, 2007) (see section II.C).

Ligand binding at the H1 receptor takes place in a stereoselective manner. The preference of one stereoisomer can be shown by different discriminative ratios for numerous compounds. Depending on the way of stereoselective orientation by stereocenter or stereoaxis and on the receptor interaction, the differences may be up to three orders of magnitude [e.g., E-configured (trans) triprolidine versus Z-configured isomer (cis)].

Point mutations in transmembrane helices IV and V show aromatic residues as potential stereoselective discriminators (Trp\textsuperscript{167}, Phe\textsuperscript{333}, Phe\textsuperscript{436}) (Wieland et al., 1999). Although with cetirizine the difference between both enantiomers is only 2-fold, the “enantiomeric shift” has been exploited to make the more potent \( (R)\)-(--) enantiomer (levocetirizine; 11) (Gillard et al., 2002b; Chen, 2008). With the tricyclic compounds, including cyproheptadine or loratadine (14; Fig. 7), some conformational isomers have been observed. Normally these compounds undergo a rapid intraconversion, but in some cases the orientation of the piperidine moiety on the bend ring system remains stable and the remaining atropisomers (conformational enantiomers) can be separated (Remy et al., 1977; Randall et al., 1979). It is unclear if these effects can also be observed in vivo. Most investigations in this direction have been made on guinea pig systems and have been verified for human H1 receptors mostly for marketed compounds only.

In view of the sedative effects of the first generation antihistamines, their clinical usefulness has proven to be limited (see below), although some of the products are currently available as over-the-counter products as sleep aids. To target the important role of histamine in allergic conditions, the class of second-generation antihistamines (e.g., levo-cetirizine (Molimard et al., 2004; Obradovic et al., 2007). Most of these compounds have an improved safety profile (Simpson and Jarvis, 2000). Fexofenadine is also less sedative, because it shows only a limited brain penetration, potentially because of its affinity for P-glycoprotein transporters (Molimard et al., 2004; Obradovic et al., 2007). Most of the second generation antihistamines (e.g., levo-cetirizine and olopatidine) share most of the properties of fexofenadine (13), including the zwitterionic nature. These compounds all show clearly improved safety profiles and have had reasonable therapeutic success.

**F. Clinical Pharmacology**

The prototypical “antihistamine” drugs chlorphenamine, clemastine, cyproheptadine, ketotifen, diphenhydramine (6), cyclizine, cinnarizine, buclizine, and promethazine (H1 receptor antagonists) have a long established place in the treatment of nausea and vomiting and allergy, specifically allergic rhinitis and conjunctivitis and anaphylactic shock, but not asthma (Bartho and Benko, 2013). Antihistamines have been formulated for local application to the nasal mucosa, eye, or skin (and together with mast cell stabilizers such as sodium cromoglicate can delay and diminish the symptoms precipitated by localized or systemic release of histamine) (Kari and Saari, 2012; Ridolo et al., 2014). Oral and topical antihistamines are used in the treatment of hay fever, insect bites/stings, and the combination of antipruritic and sedative effects is
often beneficial in removing symptoms and in restoring sleep in seasonal allergy. The sedative side effects in the workplace, or while driving, are a significant problem with the first-generation of antihistamines and provided the biorational impetus for the development of congeners that were less brain permeant (the H1 receptor crystal structure explains well the differences between first- and second-generation H1 receptor antagonists, as discussed previously in section II.A). However, a recent study highlighted the need for caution in using such drugs in older hospitalized patients, with a suggested link to onset of delirium (Rothberg et al., 2013). It is disappointing that we still have no hypnotics that mimic or facilitate/extend physiologic sleep, bearing in mind the pivotal role biogenic amines underpin in sleep physiology, arousal, and circadian regulation (Lin et al., 2011a). Nevertheless, H1 receptor antagonists have been used rarely as CNS niche drugs. For example, H1 receptor antagonists have been used for their psychosomatic effects in dermatological conditions (Gupta and Gupta, 1996), cyproheptadine is used in pediatric migraine (Lewis et al., 2004a), and close structural congeners are used as neuroleptics and antidepressants (He et al., 2013; Sato et al., 2013).

Although the newer antihistamines generally display high H1 receptor affinity and higher selectivity versus nontargets than that of the older ones, side effects can still be observed (notably antimuscarinic effects and sedation when taken with alcohol or other depressant drugs (Simons and Simons, 1999; Yanai et al., 2011). With the patent expiry of many second-generation drugs and their widespread availability over the counter at low costs, the medicine agencies are looking for genuine confidence, but there should still be a note of caution because of the lack of controlled studies in children or pregnancy for the first-generation compounds (Church et al., 2010).

### III. Histamine H2 Receptor

The H2 receptor was identified pharmacologically in 1972 based on the finding that several physiologic effects of histamine, including the stimulatory effect on gastric acid secretion, increase of heart rate, and inhibition of contraction of rat uterus were not antagonized by mepyramine (Black et al., 1972). Cloning of the H2 receptor allowed expression studies to be performed, which indicated strong expression in the stomach and brain (Gantz et al., 1991b). Clinically, H2 receptor antagonists transformed the treatment of dyspepsia, esophageal, and gastric ulcers, a trend that continued until these drugs were largely replaced by proton pump inhibitors. Apart from the brain and stomach, the H2 receptor is expressed in smooth muscle cells, chondrocytes, endothelial and epithelial cells, neutrophils, eosinophils, monocytes, macrophages, dendritic cells, T and B cells (Jutel et al., 2001, 2009).

#### A. Receptor Structure

Many years after the development of clinically useful H2 receptor antagonists, the H2 receptor was first cloned in 1991 by Gantz and colleagues from a canine genomic library, with subsequent rapid cloning of species orthologs from rat, mouse, guinea pig, and human over the subsequent four years (Gantz et al., 1991b; Ruat et al., 1991; Traiffort et al., 1995; Kobayashi et al., 1996). A single genomic clone was isolated that encoded a 1080-base pair (bp) open reading frame with a deduced 360-amino-acid polypeptide. The multiple transcription initiation sites of the human H2 receptor gene have been mapped and an 85-bp segment (−610 to −525 bp) immediately upstream of the initiation site was identified to exhibit a strong promoter activity in the gastric adenocarcinoma, MNK45, expressing the H2 receptor (Murakami et al., 1999). Several H2 receptor polymorphisms have been observed with changes, located in the gene promoter or in the coding region, including a nucleotide change leading to an Asn217Asp change (Orange et al., 1996a,b; Ito et al., 2000; Garcia-Martín et al., 2009; Micallef et al., 2013). Currently, no consensus has been obtained on a potential link of the Asn217Asp change to schizophrenia (Orange et al., 1996b; Ito et al., 2000).

Currently, there is no direct structural information available for the H2 receptor. Yet, the H2 receptor possesses many of the key prototypical amino acid residues common to the family A aminergic GPCRs, and homology modeling on the basis of the published H1 receptor X-ray structure and available mutagenesis data leads to reasonable models (Fig. 2) for the interaction of histamine with the receptor protein.
(Kooistra et al., 2013). Site-directed mutagenesis of residue Asp117 in TM3 of the canine H2 receptor (= Asp98 in the human H2 receptor) led to complete loss of [3H]tiotidine (31) binding (Kelley et al., 2001). Mutation of either—alone or simultaneously—did not abolish histamine-induced cAMP but markedly reduced its efficacy. Asp186, although it is essential for [3H]tiotidine antagonism, appears not to be crucial for cimetidine antagonism, indicating both shared and distinct sites (Gantz et al., 1992). On the basis of the mutagenesis data and molecular modeling using an H2 receptor model based on the H3 receptor X-ray structure, histamine is thought to bind with a different orientation in the binding pocket (Fig. 3).

B. Signal Transduction Mechanisms

The H2 receptor stimulates adenylyl cyclase–mediated cAMP formation in membrane preparations from various tissues as well as cAMP accumulation in various native cells (for review, see Hill, 1990, and Hill et al., 1997) and cells expressing recombinant H2 receptors (Alewijnse et al., 1998, 2000; Monczor et al., 2003). As for many adenylyl cyclase–coupled GPCRs, the H2 receptor stimulates cAMP production via the coupling to Gs proteins, as indicated by, for example, agonist-induced photofluorophore labeling. [32P]GTP azidoanilide revealed that agonist-activation of H2 receptors results in labeling of Gα-subunits with [32P]GTP azidoanilide in mammalian and insect cell expression systems (Kuhn et al., 1996; Leopoldt et al., 1997). Coupling to Gs proteins is furthermore indicated by studies with GPCR-Gα fusion proteins, which has permitted the analysis of H2 receptor/Gα coupling with high sensitivity at the level of ternary complex formation (high-affinity complex between agonist-occupied receptor and nucleotide-free G protein), guanine nucleotide exchange, i.e., [32P]GTPyS binding and steady-state GTP hydrolysis, as well as adenylyl cyclase activation (Kelley et al., 2001; Wenzel-Seifert et al., 2001). H2 receptor-Gα fusion proteins were also used to analyze ternary complex formation with guanidinetype agonists, which led to the suggestion that each agonist stabilizes a unique conformation in the H2 receptor (Kelley et al., 2001; Xie et al., 2006).

The H2 receptor does not only couple to Gs proteins but also to Gq/11 proteins, resulting in inositol phosphate formation and increases in cytosolic Ca2+ concentration in some, but not all, H2 receptor expressing cells (for previous reviews, see Hill, 1990, and Hill et al., 1997). Moreover, photoaffinity labeling studies with [γ-32P]GTP azidoanilide revealed that H2 receptor can activate both mammalian and insect cell Gq proteins in addition to Gs proteins (Kuhn et al., 1996; Leopoldt et al., 1997), whereas heterologous expression of H2 receptors in rat cardiomyocytes has also been reported to result in the interaction of recombiantly expressed H2 receptors with Gq/11, next to Gs proteins (Wellner-Kienitz et al., 2003). Interestingly, in this cell system also the Gq-cAMP-PKO pathway promotes increases in cytosolic Ca2+ concentration via the phosphorylation of L-type Ca2+ channels (Wellner-Kienitz et al., 2003).

The H2 receptor was the first histamine receptor subtype for which constitutive activation of adenylyl cyclase has been firmly established for both rat (Smit et al., 1996a) and human variants (Alewijnse et al., 1998, 2000; Monczor et al., 2003). Clinically used H2 receptor antagonists, including cimetidine (24) and ranitidine (25), behaved as inverse agonists, whereas up to now only burimamide has been described as neutral antagonist (Smit et al., 1996a). Interestingly, both rat and human H2 receptors are upregulated by prolonged receptor occupancy with inverse agonists (Smit et al., 1996a), most likely via both a reduction of cAMP-protein kinase A–mediated downregulation and a stabilization of an inherent structural instability of the H2 receptor (Alewijnse et al., 1998, 2000). So far the physiologic relevance and the structural basis of the constitutive activity of H2 receptors remain to be determined, but it is interesting to note that prolonged exposure of rabbit parietal cells to H2 receptor antagonists leads to an upregulation of H2 receptor protein, adenylyl cyclase, and ultimately to hypersecretion (Takeuchi et al., 1999). Moreover, the reported G649 allelic variant (Asn217Asn) of the human H2 receptor is reported to have reduced constitutive activity, lower histamine responses, and a diminished upregulation by ranitidine (Fukushima et al., 2001).

With respect to biased signaling, only limited information is currently available for the H2 receptor. A recent study reported that the inverse agonists ranitidine and tiotidine display positive efficacy toward extracellular signal-regulated kinase (ERK) 1/2 via a mechanism that involves Gαγ-subunits in both transfected HEK-293T cells and human gastric adenocarcinoma cells (Alonso et al., 2014). These findings suggest that H2 receptor biased signaling might be an important concept to consider.

As with many other GPCRs, the H2 receptor is desensitized and internalized upon agonist stimulation (Smit et al., 1996b; Fukushima et al., 1997). Truncations or replacements within the C-terminal tail of the receptor revealed that Thr315 was a crucial residue in agonist-dependent internalization but not desensitization (Smit et al., 1996b). Desensitization of the H2 receptor is suggested to involve both GPCR kinase 2 and 3 (Rodriguez-Pena et al., 2000; Fernandez et al., 2011). The C-terminal tail is required for membrane targeting through a putative palmitoylation-mediated mechanism (Fukushima et al., 1997), and the last 51 amino acids are reported to be crucial for internalization (Fernandez et al., 2008). Recently, the GTPase dynamin has been identified as a binding partner for the H2 receptor, both in vitro and in vivo (Xu et al., 2008). A role of dynamin, β-arrestin, and clathrin in H2 receptor
internalization has indeed also been reported (Fernandez et al., 2008).

C. Anatomic Framework

In addition to stomach and brain, in which the expression level is high, the H2 receptor is expressed in smooth muscle cells, chondrocytes, endothelial and epithelial cells, neutrophils, eosinophils, monocytes, macrophages, dendritic cells, T and B cells (Jutel et al., 2009). The anatomically important uneven distribution of H2 receptors is described here to allow understanding of the role of histamine through H2 receptors in the regulation of gastric and neuronal functions.

Molecular cloning of the H2 receptor (Gantz et al., 1991a,b; Ruat et al., 1991) allowed detection and quantification of receptor mRNA in tissues. In the dog, which was the first species to be analyzed for the H2 receptor (Gantz et al., 1991b), high expression in the fundus of the stomach and moderate in the brain was reported. In the rat, Northern hybridization analysis has revealed high expression in various parts of the brain, including cerebral cortex, striatum, hippocampus, and hypothalamus. The highest mRNA expression in the rat brain was seen in brain stem (Ruat et al., 1991; Hirschfeld et al., 1992), where several other methods have suggested important physiologic actions. In another quantitative study, the expression in the stomach was reported to be 10-fold higher than that of several brain regions (Karlstedt et al., 2001). Expression in the frontal cortex, striatum, hippocampus, thalamus, hypothalamus, pons, and medulla was rather even, whereas the cerebellum expressed a significantly lower level of mRNA. In situ hybridization showed a much more even distribution than that detected for H1 receptors and H3 receptors; although almost all brain areas expressed H2 receptor mRNA, only a few areas including the piriform cortex, granule cell layer of the dentate gyrus, and hippocampal CA1, CA2, and CA3 showed high density of grains in the forebrain. The red nucleus expresses high levels of H2 receptor mRNA. In peripheral rat organs, the stomach expresses the highest amounts of H2 receptor mRNA (Traiffort et al., 1992b).

A detailed account on H2 receptor mRNA expression in the brain of the guinea pig (Vizuete et al., 1997) as revealed by in situ hybridization suggests widespread distribution in the cerebral cortex, particularly in layers III and V; hippocampal fields CA1, CA2, C3; granular cell layer; and polymorph layer of the dentate gyrus, olfactory bulb, basal ganglia (particularly nucleus accumbens, caudate-putamen, islands of Calleja, olfactory tubercle and ventral pallidum). High expression is also characteristic of the amygdaloid complex, several thalamic, and hypothalamic nuclei. Distribution of H2 receptor mRNA and receptor radioligand binding in the rat brain are shown in Fig. 5 in comparison with H1 receptors and H2 receptors.

In human brain, H2 receptor radioligand binding is widely distributed with highest densities (measured using [125I]iodoaminopotentidine cf. 30) in the basal ganglia, hippocampus, amygdala, and cerebral cortex (Traiffort et al., 1992b). Lowest densities were detected in cerebellum and hypothalamus. A similar distribution was observed in guinea pig brain (Ruat et al., 1990). In human prefrontal cortex, cells in layer II show higher mRNA expression than the other layers, whereas the H2 receptor radioligand binding is highest in layers II and III (Jin and Panula, 2005).

In the gastric mucosa, where H2 receptor antagonists have long been known to exert inhibition of acid secretion, the H2 receptor localizes to parietal cells of the rat gastric mucosa, in more apical domains than the basal parts where HDC-expressing ECL cells, which are responsible for histaminergic regulation of parietal cell acid secretion, are localized (Panula and Wasowicz, 1993; Diaz et al., 1994). In the brain, H2 receptor expression and functions are not limited to neurons. There is a significant body of evidence suggesting the presence of H2 receptors in astrocytes (Kubo et al., 1991; Carman-Krzan and Lipnik-Stangelj, 2000) in vitro and in cultured brain endothelial cells (Karlstedt et al., 1999).

During embryonic development, H2 receptor mRNA is highly expressed in the rat brain from embryonic day 15 (Karlstedt et al., 2001). Particularly prominent expression is evident in the developing raphe area. From embryonic day 17, strong expression is found in superficial layers of the cortical plate and ventral hypothalamus. It is noteworthy that in rodents there is a distinct transient fetal histaminergic system in the raphe neurons (Auvinen and Panula, 1988; Vanhala et al., 1994), which implies that the fetal expression of H2 receptor mRNA may be functional during brain development.

Ligand binding methods for H2 receptors have also been useful to determine H2 receptor expression. Whereas early studies in guinea pig brain, lung, and transfected CHO cells have been successful using [3H]tiotidine (cf. 31) (Gajtkowski et al., 1983; Norris et al., 1984; Foreman et al., 1985; Gantz et al., 1991b), studies in rat brain and guinea pig mucosal cells were not successful (Maayani et al., 1982; Batzri and Harmon, 1986). The introduction of [125I]iodoaminopotentidine (cf. 30) was a major step forward, which provides reversible selective high-affinity binding with high sensitivity to membranes of, e.g., brain regions, and a suitable autoradiography radioligand (Hirschfeld et al., 1992). It has high affinity (Kd = 0.3 nM) for the H2 receptor in brain membranes (Martinez-Mir et al., 1990; Ruat et al., 1990; Traiffort et al., 1992a) and transfected cells expressing rat or human H2 receptors (Traiffort et al., 1992b; Smit et al., 1996a). The compound has also been used for autoradiographic mapping of H2 receptors in the mammalian brain (Ruat...
High-affinity binding is detectable in widespread regions of rodent brain. In the guinea pig, high density of binding sites is characteristic of caudate putamen, nucleus accumbens, olfactory tubercle, superficial layers I–III of the cerebral cortex, superficial gray layer of the superior colliculus, and inferior olive. Moderate binding can be found in the deep layers of the cortex, the CA1–CA4 regions of the hippocampus, anterior and lateral nuclear groups of the thalamus, and some hypothalamic nuclei (Ruat et al., 1990). In a detailed mapping study of the ligand binding sites and comparison with mRNA expression in the guinea pig brain, the distribution of binding sites corresponded rather well with the distribution of histaminergic nerve fibers. In human prefrontal cortex H$_2$ receptor binding is highest in layers II and III, although binding was detectable in all layers, and H$_2$ receptor mRNA expression is highest in layer II (Jin and Panula, 2005). Discrepancies between RNA and ligand binding patterns corresponded generally to the expected difference in the translation site (cell bodies) and the site of action of the mature receptor protein (dendritic trees of neurons) (Vizuete et al., 1997) (Fig. 8).

**D. Function**

H$_2$ receptor activation stimulates the production of cyclic AMP, protein kinase A and the transcription factor cAMP response element-binding protein, which are key regulators of neuronal physiology and plasticity (Haas and Konnerth, 1983; McCormick et al., 1991; Pedarzani and Storm, 1995; Selbach et al., 1997; Atzori et al., 2000). In the CNS, H$_2$ receptor activation can inhibit nerve cells (Haas and Bucher, 1975), but the most intriguing action is a block of the long-lasting after-hyperpolarization and the accommodation of firing, an effect with a remarkably long duration leading to potentiation of excitation in rodent (Haas and Konnerth, 1983) and human brain (Haas and Panula, 2003) (Fig. 8). A slow excitation is also common (Greene and Haas, 1990), e.g., in oriens-aleveus interneurons (Haas et al., 2008), where at the same time, the fast spiking frequency is cut by K$_v$3.2-containing potassium channel activation (Atzori et al., 2000). A long-lasting potentiation of synaptic transmission in the hippocampus is induced or markedly enhanced (Kostopoulos et al., 1988; Brown et al., 1995; Selbach et al., 1997; Haas and Panula, 2003). An increase of the hyperpolarization-activated inward current Ih (HCN2) opens the door to consciousness by depolarizing thalamic relay neurons (McCormick et al., 1991). A potassium current was blocked through H$_2$ receptors in olfactory bulb interneurons (Jahn et al., 1995). Furthermore, H$_2$ receptor activation can inhibit phospholipase A2 and release of arachidonic acid, which likely accounts for opposing physiologic responses elicited by H$_1$ receptor and H$_2$ receptor in many tissues (Traiffort et al., 1992b).

As most H$_2$ receptor ligands hardly pass the blood-brain barrier, the behavioral testing of H$_2$ receptor functions in vivo is difficult, although zolantidine (29) may be useful (see section III.E). Mice deficient in H$_2$ receptor function display cognitive deficits, an impairment in hippocampal long-term potentiation (Dai et al., 2007), and abnormalities in nociception (Mobarakeh et al., 2005, 2006), gastric, and immune functions (Jutel et al., 2001; Teuscher et al., 2004; Schneider et al., 2014a). The suppression of immune responses via the H$_2$ receptor was not only shown in H$_2$ receptor-deficient mice but also in human antigen presenting cells, where H$_2$ receptor stimulation resulted in the downregulation of numerous cytokines (Gutzmer et al., 2005; Glatzer et al., 2013).

**E. H$_2$ Receptor-Selective Ligands**

The first agonist with some selectivity for the H$_2$ receptor was 4(5)-methylhistamine (17), which is actually now used as selective H$_4$ receptor agonist (Durant et al., 1975; Lim et al., 2005) (Fig. 9). Other small molecule ligands used as H$_2$ receptor agonists...
are the aminothiazole derivative amthamine (18) (Eriks et al., 1992) and the isothiourea compound dimaprit (19), which displays moderate affinity and selectivity (Garbarg et al., 1992). Increased affinity that is higher than that of histamine is found with the longer chained guanidine derivatives arpromidine (20) or impromidine (21), although both compounds simultaneously display some H3 receptor antagonist potencies. Whereas impromidine possesses a methylated imidazole ring as with 4-methylhistamine, arpromidine has the fluorinated analogs moiety of the diaryl binding motif of the H1 receptor antagonist pheniramine (Buschauer, 1989; Leurs et al., 1995a). The homohistamine elements with the guanidine structure on both compounds are mainly responsible for activation, whereas the other elements are affinity increasing moieties (Dove et al., 2004). In this respect, the chiral forms of sopromidine are sometimes used as helpful pharmacological tools, because the (R)-(-) enantiomer sopromidine (22) is a potent H2 receptor agonist, whereas the (S)-(+)-isoform shows moderate antagonist properties in some assays.

H2 receptor agonists are not used therapeutically, although arpromidine (20) and related imidazolylpropylguanidines were developed as positive inotropic vasodilators for the treatment of severe catecholamine-insensitive congestive heart failure. More recently, aiming at improved drug-like properties, the guanidine group was replaced by an acylguanidine moiety,

Fig. 9. H2 receptor ligands.
resulting in substantially reduced basicity (by 4–5 orders of magnitude), but retaining H₂ receptor agonistic activity (Ghorai et al., 2008). Unfortunately, as also found for arpromidine- and impromidine-like compounds, numerous N²-acylated imidazolepropylguanidines (e.g., UR-AK24) proved to be poorly selective for the H₂ receptor. Some N-acylguanidines show an overlapping (partial) agonist profile for H₁ and H₂ receptors (Xie et al., 2006). However, many compounds have high affinity for H₂ receptor and H₄ receptor and were, therefore, considered as lead structures in the design of new H₃ receptor and H₄ receptor ligands (see sections IV.D and V.D). Thus, the imidazolylpropylguanidine moiety can be considered a privileged structure for histamine receptor ligands. The selectivity problem was solved by bioisosteric replacement of the imidazol-4-yl with a 2-aminothiazol-5-yl residue, optionally bearing a 4-methyl substituent as in amthamine. 2-Aminothiazoles, such as UR-BIT24, are about equipotent to the corresponding imidazoles at the H₂ receptor but devoid of noteworthy activities at H₁ receptors, H₃ receptors and H₄ receptors (Kraus et al., 2009).

Very recently, the acylguanidine motif was incorporated into bivalent ligands for the H₂ receptor, resulting in the most potent H₂ receptor agonists reported so far (Birnkammer et al., 2012). Searching for potential pharmacological tools to study hypothetical H₂ receptor dimers (Fukushima et al., 1997), two hetarylpropylguanidine moieties were connected by alkanedioyl residues varying in chain lengths (spacer lengths between 6 and 27 Å were covered). Interestingly, the highest potency resided in bivalent ligands with linkers that are, according to the model suggested by Portoghese (2001) for opioid receptor dimers, too short to allow for simultaneous occupation of the orthosteric binding pockets of both protomers of an H₂ receptor dimer. The optimal distance between the pharmacophoric groups rather suggest binding to the orthosteric and an accessory binding site of the same protomer. In accordance with the structure-activity relationships of monovalent acylguanidines, bivalent ligands comprising one or two imidazole moieties have also remarkably high activities at H₃ receptors and H₄ receptors, whereas homobivalent aminothiazoles are highly selective for the H₂ receptor. The data from the guinea pig H₂ receptor (GTPase assay, GTPγS binding assay) were largely consistent with the results from the isolated guinea pig right atrium. For instance, compounds with a decanedioyl spacer (UR-AK381, UR-AK480, UR-BIT82) were (nearly) full agonists and achieved up to 4000 times the potency of histamine at recombinant human and guinea pig H₂ receptor (Sf9 cell membranes), respectively (Birnkammer et al., 2012) (Fig. 9; Table 1).

The strong relationship of ligand binding areas responsible for receptor (in)activation can also be seen with the first marketed H₂ receptor antagonist cimetidine (24) introduced by Sir James Black (Black et al., 1972; Ganellin, 1981), because this compound with the highly polar cyano-guanidine element is comparable to the affinity increasing element in impromidine (Fig. 2). The reduced basicity of a highly polar core group can also be seen with ranitidine (nitrothendiamine) (25), famotidine (27) (sulfamoylamidine), roxatidine acetate (amide) (28), or the moderately polar compound zolantidine (aminobenzothiazole, 29), which have poor penetration into the brain with the exception of zolantidine (Baker, 2008). The imidazole moiety of cimetidine has been replaced by other bioisosteric heterocyclic moieties to reduce interaction with CYP3A4 enzymes and to overcome intellectual property issues. Although the H₂ receptor antagonists have been replaced as first regimen therapeutics in peptic ulcer disease by the proton inhibitors, they are still commonly used as safe and reliable therapeutics. Ironically one of the first "selective" H₂ receptor antagonists, the thiourea derivative burimamide (23) with low oral bioavailability used in the development of cimetidine, has also been used for the pharmacological characterization of H₃ (antagonist) and H₄ (agonist) receptors because of its affinities and properties at these receptor subtypes.

**F. Clinical Pharmacology**

The H₂ receptor antagonists cimetidine (the first to be launched by Sir James Black’s team in 1977), ranitidine (25), nizatidine (26), and famotidine (27) are well established treatments for patients presenting with dyspepsia, gastric or duodenal ulcers, or gastro-esophageal reflux disease (in the United States) (Hershcovici and Fass, 2011; Sigterman et al., 2013). Since the launch of antibiotic therapies for Helicobacter infections (based on the seminal work [Marshall and Warren, 1984; Marshall et al., 1988]) and the discovery of proton pump inhibitors (Olbe et al., 2003), the antisecretory H₂ receptor antagonists are no longer alone at the frontline (with antacids) as symptomatic treatments. Alternating treatment with proton pump inhibitors (the preferred frontline treatment) and H₂ receptor antagonists is used to treat both gastroesophageal reflux disease and more severe refractory reflux disease, e.g., esophageal ulceration or Barrett’s esophagus (Hershcovici and Fass, 2011). Treatment with H₂ receptor drugs is generally considered safe and efficacious and is available to large numbers of patients (over the counter in pharmacies for some ligands and as prescription only for others). The symptom suppression elicited by H₂ receptor drugs, however, may mask gastric cancer as has been reported for proton pump inhibitors (Wayman et al., 2000), and the drugs should be used with caution in patients with alarm symptoms. The safety profile, in part, reflects the polar nature of licensed H₂ receptor antagonists, which makes them available in the periphery, but to a lesser extent in the CNS (qualified below). Although H₂ receptor ligands (particularly agonists) have limited selectivity (particularly for H₃/H₄ receptors)
**IV. Histamine H₃ Receptor**

Histamine and its receptors were generally known as mediators connected to allergic and inflammatory reactions before the detection of the histamine H₃ receptor in 1983. Instead of its neglected neurotransmitter function as auto- as well as heteroreceptor at pre- and postsynaptic membranes and revealed its profound influence on different neurotransmitter balances. Although versatile pharmacological tools, localization of H₃ receptor, and influence on brain functions have been described in the early years, the development line was curtailed for a while. Revitalization came from the cloning of the receptor and the detection of nonimidazoline antagonists. Actually, the broad potential therapeutic indications due to the multiple neurotransmitter balance influenced by H₃ receptors raise numerous and heterogeneous possibilities in pharmaceutical industry for innovative blockbuster as well as for pipe-dreams.

**A. Receptor Structure**

The H₃ receptor was first described in 1983 on the basis of pharmacological evidence (Arrang et al., 1983). Because of the low overall homology of the H₃ receptor with either of the previous cloned H₁ receptors and H₂ receptors, it was not until 1999 that the H₃ receptor cDNA was finally cloned (Lovenberg et al., 1999). Lovenberg and colleagues used a partial cDNA clone (GPCR97) obtained from an Expressed Sequence Tags database that had significant general homology to biogenic amine receptors. The GPCR97 clone was used to probe a human thalamus cDNA library, which resulted in isolation of a full-length clone encoding a putative GPCR. Homology analysis showed the highest homology with M₂ muscarinic acetylcholine receptors and overall low homology with all other biogenic amine receptors. The cDNA encoded an open reading frame of 445 amino acids, which upon heterologous expression was responsive to histamine with an H₃ receptor pharmacological profile. The human H₃ receptor gene has been mapped to chromosome 20q13.33 and is highly expressed in the CNS (Coge et al., 2001a; Tardivel-Lacombe et al., 2001). As with the other members of the histamine receptor family, H₃ receptors are characterized by classic sequence motifs of the family A GPCRs binding biogenic amines. Currently no structural information is available, and all ligand-binding mode hypotheses are based on modeling efforts. Like for all biogenic amine receptors, the H₃ receptor contains the conserved Asp residue in TM3 (Asp1143.32), which is suggested to be involved in the binding of the ethylamine side chain of histamine (Fig. 2) (Kooistra et al., 2013). The binding mode of histamine in a homology model for the H₃ receptor furthermore suggests that the imidazole ring donates a hydrogen bond to E2065.46 in TM5, similar to the interaction with Asn1985.46 in H₁ receptor. Because the E2065.46 can form stronger bonds with the N²-nitrogen of histamine than Asn1985.46, this might also explain the substantially higher affinity of histamine for H₂ receptors (and also H₁ receptors; see Fig. 3; Tables 1 and 2) (Kooistra et al., 2013).

After the cloning of the human H₃ receptor, the receptor was cloned in other species through sequence homology screening approaches (Lovenberg et al., 1999; Coge et al., 2001a,b). The rat full-length H₃ receptor was cloned in 2000 (Lovenberg et al., 1999; Liu et al., 2000) followed by guinea pig (Tardivel-Lacombe et al., 2001), mouse (Chen et al., 2002), and monkey H₃ receptor (Yao et al., 2003). The H₃ receptor is approximately 92% conserved between the different species (Hancock et al., 2003). Despite this high conservation, substantial species differences can still sometimes be observed (e.g., Lovenberg et al., 2000).

Rare among GPCRs, the H₃ receptor gene has been reported to consist of either three exons and two introns (Tardivel-Lacombe et al., 2001; Wiedemann et al., 2002) or four exons and three introns (Coge et al., 2001a). The diverse exon/intron junctions result in alternative splice sites producing multiple, distinct
receptor isoforms (Drutel et al., 2001). The existence of multiple human H₃ receptor isoform mRNAs has opened up possible explanations to account for the pharmacological heterogeneity reported in the 1980s and 1990s for the H₃ receptor, within and across species. The reasons for this heterogeneity are complex and still not fully understood. H₃ receptor isoforms have been identified in the rat (Drutel et al., 2001; Morisset et al., 2001), mouse (Rouleau et al., 2004; Kremenov et al., 2013), and guinea pig (Tardivel-Lacombe et al., 2000).

In all mammalian species tested thus far, the full-length H₃ receptor encodes a polypeptide of 445 amino acids. The 445-amino-acid H₃ receptor is an N-linked glycoprotein with a Mr 47,000 (monomeric) and Mr 90,000 (dimeric) based on recombinant H₃ receptor 445 expressed in HEK293 cells and immunoblotting (Bakker et al., 2006). The number of H₃ receptor isoforms possible

### TABLE 2

<table>
<thead>
<tr>
<th>Compound #</th>
<th>Ligand</th>
<th>hH₁R pKᵣ[a]</th>
<th>hH₂R pKᵣ[b]</th>
<th>hH₃R pKᵣ[c]</th>
<th>hH₄R pKᵣ[d]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Histamine</td>
<td>4.6</td>
<td>5.1</td>
<td>8.2</td>
<td>8.1</td>
</tr>
<tr>
<td>2</td>
<td>2-(2-Thiazolyl)-ethylamine</td>
<td>5.3</td>
<td>&lt;5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Histaprodifen</td>
<td>5.70</td>
<td>&lt;5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Diphenhydramine</td>
<td>7.89</td>
<td>5.80</td>
<td>4.60</td>
<td>4.37</td>
</tr>
<tr>
<td>8</td>
<td>Meprobamate</td>
<td>8.80</td>
<td>4.63</td>
<td>&lt;5</td>
<td>&lt;5</td>
</tr>
<tr>
<td>10</td>
<td>Mizolastine</td>
<td>9.10</td>
<td>&lt;5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Levocetrizine</td>
<td>8.15</td>
<td>&lt;6</td>
<td>&lt;6</td>
<td>&lt;4</td>
</tr>
<tr>
<td>12</td>
<td>Terfenadine</td>
<td>7.92</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Fexofenadine</td>
<td>7.54</td>
<td>&lt;5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Loratadine</td>
<td>7.21</td>
<td>&lt;5</td>
<td>4.74</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Desloratadine</td>
<td>8.40</td>
<td>6.45</td>
<td>&lt;5</td>
<td>5.10</td>
</tr>
<tr>
<td>17</td>
<td>(4S)-Methylhistamine</td>
<td>&lt;5</td>
<td>5.10</td>
<td>4.72</td>
<td>7.73</td>
</tr>
<tr>
<td>18</td>
<td>Amantadine</td>
<td>6.82</td>
<td></td>
<td></td>
<td>5.30</td>
</tr>
<tr>
<td>19</td>
<td>Dimaprit</td>
<td>&lt;5</td>
<td>4.60</td>
<td>6.08</td>
<td>6.42</td>
</tr>
<tr>
<td>20</td>
<td>Arpromidine</td>
<td>6.5</td>
<td>6.3-8.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Imipramine</td>
<td>5.2</td>
<td>7.64</td>
<td>6.99</td>
<td>7.76</td>
</tr>
<tr>
<td>23</td>
<td>Burimamide</td>
<td>4.3</td>
<td>5.41</td>
<td>7.36</td>
<td>6.97</td>
</tr>
<tr>
<td>24</td>
<td>Cimetidine</td>
<td>4.75</td>
<td>5.84</td>
<td>4.69</td>
<td>5.03</td>
</tr>
<tr>
<td>25</td>
<td>Ranitidine</td>
<td>4.47</td>
<td>6.67</td>
<td>4.89</td>
<td>&lt;5</td>
</tr>
<tr>
<td>27</td>
<td>Famotidine</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Aminoptenitidine</td>
<td>4.60</td>
<td>7.40</td>
<td>7.10</td>
<td>&lt;5</td>
</tr>
<tr>
<td>31</td>
<td>Tiotidine</td>
<td>&lt;4</td>
<td>7.77</td>
<td>&lt;4</td>
<td>&lt;5</td>
</tr>
<tr>
<td>32</td>
<td>Nα-Methylhistamine</td>
<td>4.20</td>
<td>4.30</td>
<td>9.00</td>
<td>7.13</td>
</tr>
<tr>
<td>33</td>
<td>(R)-α-Methylhistamine</td>
<td>&lt;5</td>
<td>&lt;4</td>
<td>8.6</td>
<td>6.76</td>
</tr>
<tr>
<td>34</td>
<td>Imetit</td>
<td>4.30</td>
<td>5.10</td>
<td>9.29</td>
<td>8.48</td>
</tr>
<tr>
<td>35</td>
<td>Immepip</td>
<td>4.79</td>
<td>&lt;3.5</td>
<td>9.44</td>
<td>7.79</td>
</tr>
<tr>
<td>36</td>
<td>Methimmepip</td>
<td>6.00</td>
<td>5.70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>Proxifan</td>
<td>8.2</td>
<td></td>
<td></td>
<td>7.30</td>
</tr>
<tr>
<td>40</td>
<td>Thioperamide</td>
<td>3.88</td>
<td>4.27</td>
<td>7.6</td>
<td>7.04</td>
</tr>
<tr>
<td>41</td>
<td>Clobenpropit</td>
<td>5.45</td>
<td>5.47</td>
<td>9.0</td>
<td>7.98</td>
</tr>
<tr>
<td>42</td>
<td>Ciproxifan</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>7.1</td>
<td>5.74</td>
</tr>
<tr>
<td>43</td>
<td>Pitolisant</td>
<td>5.78</td>
<td>4.96</td>
<td>8.06</td>
<td>&lt;4</td>
</tr>
<tr>
<td>48</td>
<td>Conessine</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>8.3</td>
<td>&lt;5</td>
</tr>
<tr>
<td>55</td>
<td>MK-0249</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>8.2</td>
<td>&lt;5</td>
</tr>
<tr>
<td>56</td>
<td>Clozapine</td>
<td>8.65</td>
<td>6.92</td>
<td>&lt;5</td>
<td>6.26</td>
</tr>
<tr>
<td>58</td>
<td>JNJ-7777120</td>
<td>&lt;5</td>
<td>&lt;6</td>
<td>5.30</td>
<td>8.09</td>
</tr>
<tr>
<td>67</td>
<td>ZPL-389378</td>
<td>6.73</td>
<td>8.31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>72</td>
<td>JNJ-39758979</td>
<td>&lt;6</td>
<td>&lt;6</td>
<td>6.0</td>
<td>7.9</td>
</tr>
<tr>
<td>74</td>
<td>INCB-38579</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>6.39</td>
<td>8.3</td>
</tr>
<tr>
<td>75</td>
<td>ST-1066</td>
<td>&lt;6</td>
<td>&lt;6</td>
<td>6.29</td>
<td>7.9</td>
</tr>
</tbody>
</table>

[a] Data from Tran et al. (1978); Chang et al. (1979); Kanba and Richelson (1984); De Backer et al. (1993); Leurs et al. (1994a); Vollena et al. (1994a); Sharif et al. (1996); Merlos et al. (1997); Bakker et al. (2001); Gillard et al. (2002a); Esbenshade et al. (2003); Govoni et al. (2003); Thurmond et al. (2004, 2014a,b); Bielory et al. (2005); Xie et al. (2006); Ligneau et al. (2007); Nagase et al. (2008); Zhao et al. (2008); Sander et al. (2009); Rossbach et al. (2011); Appl et al. (2012); Shin et al. (2012); Savall et al. (2014); Where multiple values are reported, they have mostly been averaged.

[b] Data from Harada et al. (1983); Gantz et al. (1991b); Leurs et al. (1994a, 1995b); Sharif et al. (1996); Kreuter et al. (2000); Saitoh et al. (2002); Esbenshade et al. (2003); Thurmond et al. (2004, 2014a,b); Bielory et al. (2005); Lim et al. (2005); Xie et al. (2006); Preuss et al. (2007); Nagase et al. (2008); Zhao et al. (2008); Sander et al. (2009); Rossbach et al. (2011); Shin et al. (2012); Savall et al. (2014); and Levocetrizine New Drug Application #22-064; Loratadine New Drug Application #21-165. Where multiple values are reported, they have mostly been averaged.

[c] Data from West et al. (1990); Vollinga et al. (1994); Sharif et al. (1996); Kato et al. (1997); Lovenberg et al. (1999); Ligneau et al. (2000, 2007); Coge et al. (2001b); Liu et al. (2001a); Wieland et al. (2001); O’Reilly et al. (2002); Wendlendorf et al. (2002); Wulff et al. (2003); Esbenshade et al. (2003); Thurmond et al. (2004, 2014a,b); Lim et al. (2005); Ghabou et al. (2006); Nagase et al. (2008); Zhao et al. (2008); Sander et al. (2009); Mowbray et al. (2011); Rossbach et al. (2011); Appl et al. (2012); Shin et al. (2012); Andaloussi et al. (2013); Savall et al. (2014); and Levocetrizine New Drug Application #22-064. Where multiple values are reported, they have mostly been averaged.

[d] Guinea pig.
is high because of simultaneous occurrence of multiple splicing events in the same H3 receptor mRNA. The mechanisms regulating alternative splicing of the H3 receptor gene remain to be investigated.

Approximately 20 shorter human isoforms have been identified to date with deletions in the N terminus, second TM domain, and first extracellular loop, intracellular loop or at the C terminus (regions A–D; see Fig. 10). (Leurs et al., 2005). Alternative splicing in regions A (red) and/or B (orange) results in partial deletion of the N-terminal domain and/or TM2 and EL1, respectively (not shown). Such splicing events will result in nonfunctional GPCR isoforms. In contrast, distinct splice events in region C (green) results in an IL3 (intracellular loop 3) of variable length and/or deletion of TM5, -6, and/or -7. Alternative splicing in region D (blue) adds eight additional residues to the C-terminal tail of H3 receptors. Finally, a frameshift after residue 171 results in a truncated receptor protein (magenta) (Leurs et al., 2005). Isoforms that have deletions in their third intracellular loop have attracted significant interest because of the coupling of the third intracellular loop with G proteins (Drutel et al., 2001). These isoforms show variation in their pharmacological profile (Hancock et al., 2003), such as agonist potencies, signaling properties and expression patterns (Drutel et al., 2001), and constitutive activity (Morisset et al., 2001; Bongers et al., 2007b).

Regional topographical differences for the isoform mRNAs has given rise to speculation that H3 receptor heterogeneity could underlie different activities and functions of the H3 receptor in specific brain regions (Coge et al., 2001a; Drutel et al., 2001). Furthermore, there is growing evidence that homo- and hetero-oligomerization of H3 receptor isoforms occur and yield a novel regulatory mechanism (Bakker, 2004). Not all of the isoforms are likely to be expressed at the surface as a receptor, e.g., rat isoforms H3D, H3E, and H3F. These isoforms have been shown to act as dominant negatives in vitro to either directly or indirectly control surface expression of the rat isoforms H3A, H3B, and H3C (Bakker et al., 2006). Differential and overlapping expression of rodent H3 receptor isoforms has been reported (Drutel et al., 2001). Immortalized rat brain vascular endothelial cells express both the full-length isoform H3A and H3C (Karlstedt et al., 2013) Previously, Coge et al. (2001a) had shown two human isoforms that varied from the full length in terms of binding and signal transduction. To determine the biologic role of the different isoforms, the pharmacological properties of the human H3 receptor431 and the human H3 receptor965 were compared with the full-length human H3 receptor445. The human H3 receptor431 was unable to bind [125I]iodoproxyfan because of a deletion in the second transmembrane. More recently, Bongers et al. (2007b) reported, based on mRNA levels, differential expression of the human H3 receptor965 and the human H3 receptor445, with the human H3 receptor965 displaying higher expression levels than the human H3 receptor445 in many brain structures. The human H3 receptor965 also displayed higher affinity and potency for H3 receptor agonists and conversely a lower potency and affinity for H3 receptor inverse agonists. The human H3 receptor965 also displayed higher constitutive signaling compared with the human H3 receptor445 in both [35S]GTPyS binding and cAMP functional assays. Lower expression patterns were observed for the human H3 receptor415, human H3 receptor413, and human H3 receptor329, which

Fig. 10. Schematic overview of several 7TM and truncated H3 receptor isoforms. Alternative splicing in regions A (red) and/or B (orange) results in partial deletion of the N-terminal domain and/or TM2 and EL1, respectively (isoforms not shown). Distinct splice events in region C (green) results in an IL3 of variable length and/or deletion of TM5, -6, and/or -7. Alternative splicing in region D (blue) adds 8 additional residues to the C-terminal tail of H3R. Finally, a frameshift after residue 171 results in a truncated receptor protein (magenta). Truncated H3 receptor isoforms are indicated in gray.
also bind H3 receptor ligands and exhibit subtle differences in coupling to signaling mechanisms. Protein expression of the various human isoforms in brain tissue awaits confirmation and encourages the development of isoform-selective antibodies.

Genetic polymorphisms have also been identified within the human H3 receptor gene, which may further contribute to the wide diversity of the H3 receptor pharmacology. Independent publications and GenBank submissions of the human H3 receptor sequences have either a glutamic acid or aspartic acid at position 19 (Hancock et al., 2003). Another polymorphism has been identified at position 280 (IL3), an alanine to valine substitution in a patient suffering with Shy-Drager syndrome, which is also known as neurologic orthostatic hypotension, a disease characterized by neuronal degeneration and autonomic failure. Abbott Laboratories (Abbott Park, IL) confirmed this finding as well as another polymorphism at position 197, a tyrosine to a cysteine substitution (Hancock et al., 2003). Several single amino acid polymorphisms have also been identified in the third intracellular loop in rat H3 receptors (Coge et al., 2001a). Similarly, polymorphic sites are thought to be present in the mouse H3 receptors because complete sequences do not match partial sequences (Goodearl et al., 1999). For most of the reported polymorphisms no functional data are available. Yet expression of the Shy-Drager syndrome linked Ala280Val H3 receptor mutant on CHO-K1 cells showed that this mutant receptor showed reduced signaling efficacy in both cAMP signaling and \( ^{35}\text{S}\)GTP\(\gamma\)S assays (Flores-Clemente et al., 2013).

### B. Signal Transduction Mechanisms

The H3 receptor mediates pertussis toxin-sensitive \( ^{35}\text{S}\)GTP\(\gamma\)S binding in rat cerebral cortex membranes (Clark and Hill, 1996) and a variety of other brain areas and transfected cells (Rouleau et al., 2002; Bongers et al., 2007b). In addition, pertussis toxin-sensitive inhibition of N-type Ca\(^{2+}\) channels has been reported in human and guinea pig heart (for previous review, see Bongers et al., 2007a). These data point to the H3 receptor being a G\(_i\)/G\(_o\) protein–coupled receptor. In agreement with this concept, the human and rat H3 receptors recombinantly expressed in, e.g., SK-N-MC neuroblastoma cells, are negatively coupled to cAMP accumulation (Lovenberg et al., 1999, 2000). The human H3 receptor and rat H3 receptor expressed in Sf9 insect cells couple equally well to G\(_{11}\), G\(_{12}\), G\(_{13}\), and G\(_{14}\) as assessed by measurement of steady-state GTPase activity upon H3 receptor/G protein coexpression (Schnell et al., 2010).

Activation of G\(_{i/o}\) proteins by H3 receptors also results in the activation of mitogen-activated protein kinase (MAPK) pathways (Drutel et al., 2001; Giovannini et al., 2003). Using rat H3 receptor isoforms with different IL3 loops transiently expressed in COS-7 cells, Drutel et al. (2001) showed that H3 receptor agonists stimulate MAPK phosphorylation in a pertussis toxin–sensitive manner. Interestingly, the long (445-amino-acid) isoform H3A coupled considerably better to MAPK phosphorylation compared with the shorter H3B and H3C isoforms (Drutel et al., 2001). In contrast, the rat H3 receptor isoforms with deletions in the third intracellular loop were more effective to activate cAMP-responsive element-dependent transcription, compared with the full-length H3A receptor (Drutel et al., 2001). MAPK activation after H3 receptor activation is not restricted to recombinant systems but has also been observed in native tissue (Giovannini et al., 2003). In rat hippocampal CA3 cells MAPK activation via H3 receptor has been linked to memory improvement (Hill et al., 1997). Similarly, G\(_{i/o}\) activation via H3 receptors can activate PI3K, leading to the subsequent activation and phosphorylation of protein kinase B (also known as Akt). Activated protein kinase B subsequently phosphorylates and thereby inhibits the action of glycogen synthase kinase 3-\(\beta\), a major tau kinase in the brain (Bongers et al., 2007c) linked to several diseases, e.g., Alzheimer's disease.

Other pathways modulated by the H3 receptor include G\(_{160}\)-mediated increase in cytosolic calcium ion concentration (Krueger et al., 2005), inhibition of histamine synthesis and release (Torrent et al., 2005; Moreno-Delgado et al., 2006), decrease of the cytosolic Ca\(^{2+}\) concentration in sympathetic nerve endings (Silver et al., 2001, 2002), and inhibition of Na\(^{+}/\)H\(^{+}\) exchange activity (Silver et al., 2001).

In addition to agonist-induced signaling, the H3 receptor also signals in an agonist-independent, constitutive manner, thereby being one of the few GPCRs for which constitutive signaling has been observed in vivo. Both the rat H3 receptor and human H3 receptor exhibit high constitutive activity, resulting in high basal GTP\(\gamma\)S binding (Morisset et al., 2000; Rouleau et al., 2002). The high basal GTP\(\gamma\)S binding is inhibited by inverse agonists such as thioperamide and ciproxifan. Moreover, constitutive activity of the H3 receptor results in inhibition of forskolin-stimulated cAMP accumulation in recombinant systems, agonists further decreasing cAMP accumulation, and inverse agonists enhancing cAMP accumulation (Wieland et al., 2001). Moreover, constitutive H3 receptor activation leads to increased arachidonic acid release and inhibition of neurotransmitter release in vivo (Morisset et al., 2000; Rouleau et al., 2002).

Like the other histamine receptors, H3 receptors are able to form homo- and heterodimers (Panula and Nuutinen, 2013). Whereas the biochemical evidence seems to indicate that the H3 receptor isoforms can form homo- and heterodimers, the direct relevance for signaling or functional responses has not been elucidated. Behavioral and signaling studies have provided more conclusive evidence that H3 receptor can form
functional heterodimers with dopamine receptors (Ferrada et al., 2008, 2009). Activation of H₃ receptors inhibits D₁ receptor agonist SKF-81297–induced cAMP accumulation in slices of striatum (Sanchez-Lemus and Arias-Montano, 2004) and inhibits D₁ receptor-dependent release of [³H]GABA from rat striatum (Arias-Montano et al., 2001). Furthermore, in transfected cells, H₃ receptor or D₁ receptor signaling can be blocked not only by the selective respective antagonist but also by a selective antagonist of the partner receptor (Ferrada et al., 2009), and H₃ receptor or D₁ receptor antagonists can block MAPK signaling induced by H₃ receptor or D₁ receptor agonists (Moreno et al., 2011) in the brain. In this context, it is interesting that histaminergic neurons, which project to the striatum, contain dopa-decarboxylase and can produce dopamine after uptake of dopa that can be released from nearby dopaminergic neurons or is available in patients treated with L-dopa for Parkinson’s disease (see Yanovsky et al., 2011).

C. Anatomic Framework

Cloning of the H₃ receptor in 1999 allowed verification of the high expression of the receptor in the brain (Lovenberg et al., 1999). This first report also established that the H₃ receptor is abundantly expressed in very important areas of the brain (Fig. 5), e.g., cerebral cortex, thalamus, caudate putamen, ventromedial nucleus of the hypothalamus, and several aminergic projection systems, including histaminergic tuberomamillary nucleus (TMN) neurons and the noradrenergic neurons of locus coeruleus. Subsequently, detailed analyses of H₃ receptor mRNA expression in rat brain (Pillot et al., 2002b) and findings on differential expression of the H₃ receptor isoforms (Drutel et al., 2001) have further contributed to the current understanding that the H₃ receptor plays important roles in multiple functions in the CNS. In the cerebral cortex of the rat, intense labeling in in situ hybridization samples was characteristic of layers V in most cortical areas and in layer III (particularly in the secondary motor cortex), granular layer IV of the auditory cortex, and layer VI of the somatosensory and auditory cortices (Pillot et al., 2002a). Expression of the different splice forms in the rat brain shows differences that may be functionally significant: there are differences in expression patterns at least in the cerebral cortex, hippocampus, and cerebellum (Drutel et al., 2001). The distribution of H₃ receptor mRNA and ligand binding in comparison with the H₁ and H₂ receptor are shown in Fig. 5.

In human brain, the expression of H₃ receptor mRNA in the prefrontal cortex is higher in layer V than in any other layer in Brodmann’s areas 8–11,24, 32,44, 45, 46, and 47, i.e., in almost all areas investigated (Jin and Panula, 2005). In contrast, the [³H]N⁴-methylhistamine binding in the same samples is highest in layers III and IV, suggesting that most of the receptors occur either on the dendrites of the pyramidal neurons or in the thalamocortical axons. The lowest binding density is seen in the superficial layer I and deep layer VI (Jin and Panula, 2005).

H₃ receptor mRNA is expressed at a high intensity in the human dorsal thalamus, the only part of thalamus that projects to the cortex. High to moderate expression is found in most of the principle relay nuclei (anterior, lateral, and medial nuclei, lateral geniculate nucleus), midline, and internal medullary laminar nuclei, whereas the expression level is low in the medial geniculate nucleus, posterior thalamic region (pulvinar), and the ventral thalamus (reticular nucleus, zona incerta). The expression is particularly abundant in the associate relay areas that project to the prefrontal cortex, notably the mediodorsal thalamic nucleus (Jin et al., 2002). H₃ receptor binding sites are detectable using [³H]N⁴-methylhistamine also in human thalamus (Jin et al., 2002). The highest density of binding sites was seen in the midline nuclei (reuniens, paraventricular, subhabenula), mediodorsal nucleus, some of the internal medullary laminar nuclei (parafascicular, paratenial, fasciculosis), and parts of the pulvinar (medial, inferior, diffuse). The binding level is generally low in other parts of the thalamus. This distribution is in agreement with the concept that thalamic neurons, which express H₃ receptors, project to the cortex, where radioligand binding is detected on presynaptic terminals.

In the basal ganglia, H₃ receptor mRNA signal intensity is observed in decreasing order in the following structures: putamen > frontal cortex > globus pallidus externum > globus pallidus internum (Anichtchik et al., 2001). In the mesencephalon (at the level of the superior colliculus), in substantia nigra, H₃ receptor mRNA in situ signal is very low or undetectable, whereas a specific signal is observed in the red nucleus. In the corpus striatum, the highest expression of H₃ receptor mRNA is detected in the putamen, whereas in the paleostriatum the expression is low and barely higher than the nonspecific background (Anichtchik et al., 2001). In normal human brain, the H₃ receptor radioligand binding level is found in decreasing order: substantia nigra > putamen > globus pallidus externus > globus pallidus internus > frontal cortex (Anichtchik et al., 2001). This distribution suggests that the striatonigral projection neurons express H₃ receptors, which is likely to regulate the release of GABA within the substantia nigra. No evidence for expression of H₃ receptors in human dopaminergic nigral neurons was found in one study (Anichtchik et al., 2001). In Parkinson’s disease, H₃ receptor mRNA expression in the pallidum externum is elevated compared with the normal brains. In Parkinson’s disease substantia nigra, an increase of the receptor binding density has been detected (Anichtchik et al., 2001). This increase in receptor binding coincides with a clear increase in histamine content (Rinne et al., 2002) and histamine-immunoreactive nerve fibers (Anichtchik et al., 2000) in
substantia nigra, suggesting that either the disease process itself, e.g., through an effect of decreased dopamine or associated medication, modifies the histaminergic system.

During embryonic development, the H₃ receptor is expressed early (from embryonic days 14 and 15 onward) in the CNS of the rat (Heron et al., 2001; Karlstedt et al., 2003). The expression is prominent in the midbrain ventricular epithelium, in medulla oblongata, and spinal cord, which suggests developmental roles for H₃ receptors, and in brown fat, which suggests a role in energy metabolism or development of these cells (Karlstedt et al., 2003). In another study, which used cRNA probes instead of an oligonucleotide probe, a more widespread distribution of H₃ receptor mRNA in developing rat tissues was observed, with significant signals in spinal ganglia, salivary glands, respiratory epithelium, gastric and intestinal mucosa, skin, thymus, liver, heart, and kidney (Heron et al., 2001). This widespread distribution indicates that during development, H₃ receptor functions may extend well beyond the nervous system.

Antibodies have been generated against synthetic peptides from the human and rat H₃ receptors to localize the receptor protein in mammalian tissues. One of these antibodies detects immunoreactive species at 62 and 93 kDa in mouse brain (Chazot et al., 2001). Immunoreactivity was localized in pyramidal neurons of lamina V of the rodent cerebral cortex and in medium-sized neurons in the striatum, cerebellar Purkinje cells, and the pyramidal cell layer of the hippocampus (Chazot et al., 2001). The H₃ receptor mRNA distribution in rat (Pilot et al., 2002a) and human (Jin and Panula, 2005) cortex is mainly in deep laminae, whereas the receptor radioligand binding is more even (Pilot et al., 2002a; Jin and Panula, 2005). The receptor immunoreactivity could be expected in the same areas as radioligand binding, which motivates further studies using parallel immunocytochemistry with in situ hybridization and/or radioligand binding analysis to verify the results. In adult rat stomach, the H₃ receptor is found in ECL cells, which also express HDC (Grandi et al., 2008). In the sensory system of the rat and mouse, H₃ receptor immunoreactivity resides in large Aδ fibers that terminate in Meissner’s corpuscles surrounded hair follicles (Cannon et al., 2007). In dorsal root ganglia, H₃ receptor immunoreactivity was localized in medium-sized and large cells, which also expressed calcitonin gene-related peptide; H₃ receptor KO mice did not show this expression, suggesting selectivity of labeling. The localization suggests that H₃ receptor containing fibers are involved in high-threshold mechanical nociception. Epidermal Merkel cells and keratinocytes also express H₃ receptor-like immunoreactivity. In the locus coeruleus, histamine activates, through H₂ receptors, noradrenergic neurons that inhibit neuropathic pain. This descending inhibition may be facilitated through blocking the H₃ receptor-mediated autoinhibition of histaminergic terminals in the locus coeruleus (Wei et al., 2014).

Although presence of the H₃ receptor in rodent sensory ganglia on a subset of Aδ fibers and lack of reactivity in H₃ receptor KO mice has been shown using immunocytochemistry (Cannon et al., 2007), H₃ receptor expression in peripheral ganglia using in situ hybridization has not been systematically analyzed. Particularly many commercial antibodies against the H₃ receptor are nonspecific: they detect multiple unrecognized bands in Western blot analysis and also react in tissues of H₃ receptor KO mice. Thus the specific neuronal phenotypes in autonomous and sensory ganglia that express H₃ receptors are still unknown in most cases.

The apparent high affinity of (R)-α-methylhistamine (33) for the H₃ receptor has enabled the use of this compound as a radiolabeled probe (Arrang et al., 1987b). This compound has been successfully used to identify a single binding site in rat cerebral cortical membranes, which in phosphate buffer has the pharmacological characteristics of the H₃ receptor (Arrang et al., 1987b, 1990). [³H](R)-α-Methylhistamine binds with high affinity (Kᵢ = 0.3 nM) to rat brain membranes, although the binding capacity is generally low (approximately 30 fmol/mg protein; Arrang et al., 1987b). It should be noted that this ligand has a moderate affinity for the H₄ receptor (Liu et al., 2001b), and so the anatomic profile may be incomplete.

Radiolabeled H₃ receptor antagonists have been available since the early 1990s. The first compound to be developed was [¹²⁵I]iodophenpropit, which has been used to successfully label H₃ receptors in rat brain membranes (Jansen et al., 1992). Inhibition curves for thioperamide and iodophenpropit were consistent with interaction with a single binding site, but H₃ receptor agonists were able to discriminate high [4 nM for (R)-α-methylhistamine]- and low [0.2 mM for (R)-α-methylhistamine]-affinity binding sites (Jansen et al., 1992). More recently, [³H]GR16820 (Brown et al., 1994) and [¹²⁵I]iodoproxyfan (Ligneau et al., 1994) have also proved useful as high-affinity radiolabeled H₃ receptor antagonists. [¹²⁵I]iodoproxyfan (Stark et al., 1996) is the most potent and selective ligand available at the present time, with a Kᵢ of 65 pM (Ligneau et al., 1994). In rat striatum, in the presence of guanine nucleotides such as guanosine (3-thiotriphosphate) (GTPγS), 40% of the binding sites exhibited a 40-fold lower affinity for H₃ receptor agonists, providing further evidence for a potential linkage of the H₃ receptor to G proteins (Ligneau et al., 1994). [³H]Thioperamide and [³H]5-methylthioperamide have also been used to label H₃ receptors in rat brain membranes (Yanai et al., 1994; Alves-Rodrigues et al.,...
In the rat brain, the histamine stimulated \(^{35}\text{S}\)GTP binding assays can be used to detect receptor-dependent activation of G proteins (Wieland et al., 1994). This method can be used to locate anatomic patterns of G protein activation in tissues. In the rat brain, the histamine stimulated \(^{35}\text{S}\)GTP binding corresponds to the H3 receptor radioligand binding pattern and responds to H3 receptor antagonists, suggesting that histamine-induced signals are due to activation of H3 receptors (Ichinose and Barnes, 1990). By using this method, it has been shown that in hibernating ground squirrels the H3 receptors, which are upregulated in caudate putamen during hibernation bout, can be activated throughout the hibernation cycle (Sallmen et al., 2003a). This, together with the increased histamine turnover during hibernation (Sallmen et al., 1999), indicates that histamine may be a critical factor in maintaining the hibernation state.

In addition to data obtained from ligand binding and \(^{35}\text{S}\)GTP\(_\gamma\)S binding studies, evidence for the localization of H3 receptors has also come from functional studies involving inhibition of neurotransmitter release and electrophysiology. The histaminergic neurons located in the tuberomamillary nucleus of the posterior hypothalamus project throughout the central nervous system. Histamine production and release is under feedback control through autoreceptors (H3 receptors); however, a large number of nonhistaminergic neurons, including their axon varicosities, carry H3 heteroreceptors. This makes the prediction of H3 receptor-mediated effects difficult but opens up an avenue to multiple interference with neural functions (Fig. 11).

Candidate drugs as clinical PET tracers to both study the H3 receptor system and measure receptor occupancy of H3 receptor therapeutic compounds have been developed (Selivanova et al., 2010). \(^{11}\text{C}(1R,40R)-5\text{-Methoxy-N-methyl-3-oxo-N-(2-piperidin-1-ylethyl)-3H-spiro[2-benzofuran-1,10-cyclohexane]-40-carboxamide and} ^{18}\text{F}(1R,40R)-5\text{-Fluorodideuteromethoxy-N-methyl-3-oxo-N-(2-piperidin-1-ylethyl)-3H-spiro[2-benzofuran-1,10-cyclohexane]-40-carboxamide bind specifically to sections of rhesus monkey and human brain, where substantia nigra, nucleus accumbens, and globus pallidus show strong signals. PET imaging on rhesus monkey brain shows strong signals in the striatum and frontal cortex and lower signals in the cerebellum (Hamill et al., 2009).

**D. Function**

The H3 receptor was first characterized as an autoreceptor regulating histamine synthesis and release from rat cerebral cortex, striatum, and hippocampus (Arrang et al., 1985a,b, 1987a, 1988a). H3 receptor-mediated inhibition of histamine release has also been observed in human cerebral cortex (Arrang et al., 1988b). Differences in the distribution of H3 receptor binding sites and the levels of histidine decarboxylase (an index of histaminergic nerve terminals) suggested at an early stage that H3 receptors were not confined to histamine-containing neurons within the mammalian CNS (Arrang et al., 1987a; van der Werf and Timmerman, 1989). This has been confirmed by the observations that H3 receptors can regulate serotoninergic (Schlicker et al., 1988, 1989; Threlfell et al., 2004), noradrenergic (Schlicker et al., 1989), cholinergic (Clapham and Kilpatrick, 1992), and dopaminergic (Schlicker et al., 1992, 1993; Munari et al., 2013) neurotransmitter release in mammalian brain. H3 receptor activation inhibits the firing of the histamine neurons in the posterior hypothalamus through a mechanism distinct from autoreceptor functions found on other amineergic nuclei, namely a block of Ca\(^{2+}\)-current, which is part of the pacemaker cycle in histaminergic neurons (Stevens et al., 2001) (Fig. 12). Electrophysiological evidence for reduction of excitatory transmitter release (glutamate) has been presented by Brown et al. (Brown and Reymann, 1996; Brown and Haas, 1999). Activation of H3 receptors inhibits neurotransmission also in the peripheral autonomous and sensory systems. Hypothalamic neurotransmitter release is regulated by H3 receptor in guinea pig mesenteric artery (Ishikawa and Sperlaklis, 1987), human saphenous vein (Molderings et al., 1992), guinea pig atria (Endou et al., 1994), human heart (Imamura et al., 1996), rat tail artery (Godlewski et al., 1997), and dog kidney (Yamasaki et al., 2001). Neuropeptide (tachykinins or calcitonin gene-related peptide) release from sensory C fibers from airways (Ichinose and Barnes, 1990), meninges (Matsubara et al.,

![Fig. 11. Neuronal targets of histaminergic neurons. H1 receptor and H2 receptor are located on many neurons where they mediate the activity in several ways (see text). H3 receptors are located on histaminergic neuron somata, dendrites, and axons to control firing, histamine synthesis, and release acting as autoreceptors. As heteroreceptors they control transmitter release from a wide variety of nonhistaminergic axons and in some cases inhibit the activity of nonhistaminergic neurons. Modified from Haas and Panula (2003).](image-url)
Indeed, infusion of histamine in the hippocampus of regulation of hibernation or arousal from the bout. (Sallmen et al., 1999), which suggests that histamine may be involved in during the hibernation period (Sallmen et al., 1999), which suggests that histamine may be involved in regulation of hibernation or arousal from the bout. Indeed, infusion of histamine in the hippocampus of golden-mantled ground squirrel causes a delayed arousal (Sallmen et al., 2003b).

As autoreceptors on somata, dendrites, and axons of TMN neurons, constitutively active H3 receptors (Arrang et al., 2007) inhibit cell firing (Stevens et al., 2001), as well as histamine synthesis and release from varicosities (Arrang et al., 1983; Torrent et al., 2005; Moreno-Delgado et al., 2006). This autoinhibition by H3 receptor agonists [e.g., (R)-α-methylhistamine; (33)] and its removal by H3 receptor antagonists/partial agonists can be demonstrated in recordings from TMN neurons. As presynaptic heteroreceptors, H3 receptors control the release of several other transmitters, including biogenic amines (Schlicker et al., 1994, 1999), acetylcholine (Blandina et al., 1996; Arrang, 2007), GABA (Jang et al., 2001), and glutamate; field potentials evoked by stimulation of glutamate fiber bundles, e.g., in hippocampus or striatum, show a marked decrease in the presence of an H3 receptor agonist (Brown and Haas, 1999; DoreuLeele, 2001) (Fig. 12). In this context, the H3 receptor has been shown as a potential therapeutic target for cerebral ischemia (Yan et al., 2014). Heterogeneity of the histaminergic neurons with respect to function and projections has been demonstrated by Giannoni et al. (2009); activation of histaminergic neurons by blocking the somatic autoreceptors causes differential release of histamine measured by microdialysis in different target regions of rats; cortex and nucleus basalis display strong increases of histamine release, but both the ventral and the dorsal striatum, regions receiving ample innervation too, do not show any such release (Blandina, et al., 2012). H3 autoreceptors may thus have been absent, or not activated, in the histaminergic neurons projecting to these latter regions.

H3 receptor KO mice display changes in behavioral states, reduced locomotion (Toyota et al., 2002; Schneider et al., 2014b), a metabolic syndrome with hyperphagia, late-onset obesity, increased insulin and leptin levels (Tøfftegaard et al., 2003; Yoshimoto et al., 2006), and an increased severity of EAE, a model of multiple sclerosis (Teuscher et al., 2004, 2007). By comparing EAE-susceptible and -resistant mice strains as well as H3 receptor KO mice, a functional link between central H3 receptor signaling and peripheral immune responses was proposed (Krementsov et al., 2013).

Fig. 12. Electrophysiological actions of H3 receptor activation in brain slices. (A1) Typical regular firing of a histaminergic tuberomamillary neuron. (A2) Block of the H3-autoreceptor activation by thioperamide releases the inhibition and thus increases firing rate. (B) Ca2+-current in response to depolarization of histaminergic neuron is reduced by the H3 receptor-agonist R-α-methylhistamine (33). (C) Glutamatergic cortico-striatal synaptic transmission (co-str) is reduced by R-α-methylhistamine, an example of an H2-heteroreceptor action.
release (Ea Kim et al., 1992). Finally, there is a report that H₃ receptor activation can stimulate adrenocorticotropic hormone release from the pituitary cell line AtT-20 (Clark et al., 1992).

E. H₃-Selective Ligands

A large number of potent ligands for the H₃ receptor have been described, encompassing significant structural diversity. Many of these have been reported as useful pharmacological tools for in vitro or in vivo study and are described here. The number of ligands and structural genera is large, and a number of comprehensive reviews of the structure-activity relationship (SAR) and properties of H₃ receptor ligands have been published (Celanire et al., 2005; Amon et al., 2007; Berlin and Boyce, 2007; Esbenshade et al., 2008; Sander et al., 2008; Gemkow et al., 2009; Tiligada et al., 2009; Lazewska and Kiec-Kononowicz, 2010; Berlin et al., 2011).

1. Agonists. Histamine (1), 2-(1H-imidazol-4-yl)ethanamine, is of course the endogenous ligand for histamine receptors, and other imidazole analogs have proven to be useful tools for pharmacological studies (Fig. 13). The methylated analog [3H]Nα-methylhistamine (32) (Arrang et al., 1987a) is not selective for H₃ receptors versus H₁ and H₂ receptors but because of its high affinity (rat H₃ receptor Kᵩ = 2 nM) (Arrang et al., 1983; Hill et al., 1997) and ready availability in tritiated form has found wide use in radioligand competition binding assays. (R)-α-Methylhistamine (33) is highly potent (Kᵩ = 0.5 nM in rat brain) (Arrang et al., 1985b, 1987b; Hill et al., 1997) and is also used as an in vitro agonist tool. (R)-α-Methylhistamine does have significant H₄ receptor activity (binding pKᵩ of 6.85, human H₄ receptor in transfected cells) (Liu et al., 2001a,b; Morse et al., 2001) and pKᵩ = 6.1 at rat H₄ receptor. This agonist also induces water drinking in rodents, a finding used as the basis of a novel pharmacological assay (Clapham and Kilpatrick, 1993; Ligneau et al., 1998; Fox et al., 2002). Prodrugs of (R)-α-methylhistamine have been described with an improved pharmacokinetic profile (Krause et al., 2001; Stark et al., 2001).

Imetit (34) is a readily available potent agonist (rat H₃ receptor Kᵩ = 0.1 nM) demonstrating the expected profile of an agonist in vivo, decreasing histamine release ex vivo and turnover (Eriks et al., 1992; Garbarg et al., 1992). More lipophilic ligands have also been described with improved properties. Immepip (35) has high affinity at H₃ receptors but poor selectivity versus H₄ receptors. However, methylation of methimmepip (36) gives an agent with excellent potency (human H₃ receptor Kᵩ = 1 nM), agonism (α of 0.9 versus histamine), and selectivity (>2000-fold selectivity over H₁, H₂ receptors and H₄ receptors). Importantly, methimmepip profoundly reduced CNS microdialysate histamine levels at low doses (5 mg/kg i.p.) (Kitbunnadaj et al., 2005). Other lipophilic agonists have also been described in an extensive SAR study (Govoni et al., 2006), and an agonist (37) (human H₃ receptor Kᵩ = 0.17 nM, 77% efficacy) was active in vivo in mice in blocking aggression and stress (Ishikawa et al., 2010). Other H₃ receptor agonists have been described with novel structural variations, including immethridine (human H₃ receptor Kᵩ = 0.9 nM, 90% agonist efficacy), an analog of immepip wherein the highly basic piperidine moiety is replaced by a less basic pyridinyl moiety (Kitbunnadaj et al., 2004). A particularly interesting ligand is the "protean" (Kenakin, 2002) agonist proxyfan (38) (Gbabou et al., 2003), a compound that does not fit neatly into a rigid categorization of agonist or antagonist, because its properties have been found to depend on the system assessing efficacy, with full agonism, neutral antagonism, and inverse agonism seen. Several other imidazole-containing H₃ receptor ligands have been described, e.g., GT-2331 (39), with some having assay-dependent profiles (Tedford et al., 1999; Liu et al., 2004; Ito et al., 2006).

2. Antagonists. A number of named antagonist ligands have figured prominently in preclinical studies, with clear ability to release neurotransmitters and having efficacy in preclinical animal models. This has motivated continuing research on improved agents with potency, selectivity, and better drug likeness to enable clinical evaluation. Computer modeling strategies...
have been adopted widely in recent years for ligand docking and pharmacophore screening purposes (Schlegel et al., 2007; Levoin et al., 2008) (Fig. 14).

A number of antagonists have advanced to phase I testing and phase II efficacy trials for a number of conditions, including sleep disorders, cognitive disorders in schizophrenia, Alzheimer’s disease, attention deficit hyperactivity disorder, and allergic rhinitis.

The first H₃ receptor antagonists were imidazole based, and before the identification of the H₄ receptor, several were widely used “H₃ receptor standards” for preclinical studies, also because of their availability from commercial sources, including thioperamide (40), clobenpropit (41), and ciproxifan (42). Thioperamide is highly potent at rat H₃ receptors with \( K_i = 4.3 \) nM (Arrang et al., 1987a; Hill et al., 1997) that has been found effective in vivo in a large number of behavioral models, including elevated plus maze learning, Morris water maze, Barnes maze (Miyazaki et al., 1995; Komater et al., 2005), and others. Clobenpropit (41) is likewise highly potent in vitro, with \( pA_2 = 9.92 \) in the guinea pig ileum assay (Eriks et al., 1992) and activity in vivo, e.g., in models of working memory, seizure, and Alzheimer’s disease (Yokoyama et al., 1994; Zhang et al., 2003; Harada et al., 2004; Huang et al., 2004; Bardgett et al., 2011). Clobenpropit and thioperamide, however, also have potent activity at H₄ receptors (Lim et al., 2009), and thioperamide also is active at 5HT₃ receptors (Leurs et al., 1995b). Ciproxifan is a potent (rat H₃ \( K_i = 0.5 \) nM) and selective (Ligneau et al., 1998; Stark et al., 2000) ligand with oral bioavailability, which is effective in a number of preclinical animal models and, thus, has found extensive use as an in vivo reference antagonist, for example, in attentional models, such as electroencephalogram-assessed waking and impulsivity (Komater et al., 2005; Hancock, 2006; Day et al., 2007). SCH-79687 (43) is a highly potent (rat H₃ receptor \( K_i = 1.9 \) nM) antagonist that reduced congestion in animal models of allergic rhinitis when coadministered with an H₁ receptor antagonist; evidence supports the hypothesis that the efficacy of H₃ receptor antagonists is mediated through peripherally mediated release of norepinephrine from nasal mucosa, because this compound was virtually nonbrain penetrant with a brain/plasma ratio of 0.02 (Varty and Hey, 2002; McLeod et al., 2003).

Nonimidazoles have become the main focus of the H₃ receptor antagonist design work in recent years, because these structures address the class-related issues noted with the early generation of imidazole-based agents, including cytochrome P450 inhibition, relatively poor CNS penetration, and incidence of off-target activity at H₄ receptors or other receptors (Berlin et al., 2011). The first SAR study of potent nonimidazole antagonists disclosed UCL-1972 (44), with rat H₃ receptor \( K_i \) of 39 nM. In this structure, the imidazole ring was replaced with a tertiary basic amine (Ganellin et al., 1995). Nonimidazoles as a class have proven much more supportive of combining cross species at rat and human receptors with good drug likeness (CNS penetration, minimal cytochrome P450 inhibition) (Ganellin et al., 1998; Meier et al., 2001). There has been rapid progress in the last decade in finding antagonists with excellent in vivo efficacy in diverse preclinical models, and several prominent compounds have been detailed in the literature. Of particular interest is pilotisplant (45), also previously known as BF-2.649, BP-2649, or tiprolisant (cf. Meier et al., 2001). This potent (rat \( K_i = 17 \) nM, human \( K_i = 5 \) nM) antagonist entered clinical trials for a number of indications and has been well characterized preclinically as able to promote wakefulness in animals and humans (Ligneau et al., 2007; Lin et al., 2008; Schwartz, 2011). Antagonists with a second basic amine moiety have been widely described as highly potent, with JNJ-5207852 (46) having rat and human \( K_i \) of 1.2 and 0.6 nM, and the acetylene analog JNJ-10181457 (47) having a rat and human H₃ receptor \( K_i \) of 7 and 1.2 nM. These two agents were reported to promote wakefulness in rat, mouse, and dog models (Barbier et al., 2004; Bonaventure et al., 2007), a property of H₃ receptor antagonists as a class (Barbier and Bradbury, 2007). A number of synthetic diamine-containing H₃ receptor antagonists have been described with high in vitro potency. One example of a potent agent is the natural product alkaloid conessine (48), with a human H₃ receptor \( K_i \) of 5.4 nM, rat H₃ receptor \( K_i \) of 25 nM. The core has been elaborated to analogs, whereas the potency and commercially availability of conessine itself suggest potential utility as a tool compound (Cowart et al., 2007; Santora et al., 2008; Zhao et al., 2008). The benzofuran ABT-239 (49) (human H₃ receptor \( K_i = 0.45 \) nM, rat H₃ receptor \( K_i = 1.35 \) nM) has been used as a reference antagonist with potent in vivo efficacy in a number of animal models of attention, cognition, schizophrenia, ethanol-associated learning deficit, and Alzheimer’s disease (Cowart et al., 2005; Fox et al., 2005; Varaschin et al., 2010; Bitner et al., 2011). Heterocyclic benzofuran A-688057 (50) was likewise highly brain penetrant, potent in vitro (human H₄ receptor \( K_i = 0.5 \) nM, rat H₃ receptor \( K_i = 3 \) nM) and effective in animal models in vivo at modest levels of H₃ receptor occupancy (Cowart et al., 2007). GSK-189254 (51) (human H₃ receptor \( K_i = 0.1 \) nM, rat H₃ receptor \( K_i = 0.7 \) nM) has been described as broadly effective in a number of animal models, including attentional, memory, pain, and narcolepsy models (Guo et al., 2009; Medhurst et al., 2007; McVaraughty et al., 2012). GSK-189254 (51) has also been synthesized in an \(^{11}C\)-labeled form and used as a PET tracer to empirically measure H₃ receptor occupancy of test compounds in intact animals and in the clinic (Ashworth et al., 2010). GSK-207040 (52) (human H₃ \( K_i = 0.2 \) nM, rat H₃ \( K_i = 0.8 \) nM) and GSK-334329 (53) (human H₃ receptor \( K_i = 0.3 \) nM, rat H₃ \( K_i = 0.8 \) nM) were both found effective in models of neuropathic
pain and capsaicin-induced tactile allodynia and scopolamine-induced memory impairment (Medhurst et al., 2007). A separate report found efficacy in an osteoarthritis pain model for GSK-189254, GSK-334429, and ABT-239 (Hsieh et al., 2010b). Recently, the compound JNJ-39220675 (54) (human H3 receptor \( K_i = 1.4 \) nM) was found to reduce ethanol intake in ethanol-preferring rats (Galici et al., 2011) and was found to have decongestant efficacy in an early clinical trial in subjects with allergic rhinitis (Barchuk et al., 2013).

F. Clinical Pharmacology

After a decade of intensive studies (Ligneau et al., 2007; Lin et al., 2008; Schwartz, 2011), a range of H3 receptor inverse agonists/antagonists have entered advanced clinical development in the last 5 years, with the most advanced being pitolisant (BF2.649, 1-piperidine, hydrochloride, pitolisant, Wakix, 45) (Dauvilliers et al., 2013) having been officially filed for licensing by Bioprojet early in 2014 for use in refractory narcolepsy. This is the completion of an impressive research story spanning 40 years, initiated back in the mid-1970s, when histamine was first described as a neurotransmitter, and the pharmacological and molecular identification of the H3 receptor in the mid-1980s and late-1990s, respectively. Narcolepsy is characterized by excessive diurnal sleepiness and can occur alone or as part of other neurologic disorders (e.g., Parkinson’s disease). On the basis of the wake-inducing properties of H3 receptor blockade, pitolisant (45) was developed, together with an apparent ideal pharmacokinetic profile, where a once-a-day dose maintains attention over the day, but, importantly, allows individuals to sleep at night (Iannone et al., 2010; James et al., 2011; Schwartz, 2011). Preclinical studies have also suggested the lack of drug abuse liability.
for pitolisant in rodent and primate models, in contrast to modafinil (Uguen et al., 2013). In a double-blind, randomized, parallel-group controlled trial performed with 95 cases recruited across Europe in 32 sleep centers, pitolisant at doses up to 40 mg was efficacious on excessive daytime sleepiness compared with placebo. Over the 8-week treatment period, mean Epworth Sleepiness Scale score reductions were $-3.4$ in the placebo group, $-5.8$ in the pitolisant group, and $-6.9$ in the modafinil group. Pitolisant was well tolerated (with only one patient displaying a serious side effect, namely abdominal discomfort) compared with the previous gold standard, modafinil, where multiple issues arose (Dauvilliers et al., 2013). A recent retrospective study determined the benefits of pitolisant in patients with idiopathic hypersomnia and narcolepsy refractory to stimulants, including modafinil. Twenty-three to thirty-eight percent of the 78 patients receiving pitolisant (daily 5- to 50-mg dose) displayed a positive benefit-risk ratio (Leu-Semenescu et al., 2014).

A more modest study with an H$_3$ receptor inverse agonist, MK-0249 (55) did not significantly affect maintenance of wakefulness test battery. However, the pattern of improvement on a range of subjective ratings and psychomotor performance end points suggested that MK-0249 (55) improved some aspects of cognition and performance not captured by the maintenance of wakefulness test (Herring et al., 2013). A number of other compounds developed by major players in this field have been investigated, with multiple trials listed in www.clinicaltrials.gov to date but yet to be reported. These include a series of phase I PET occupancy trials with PF-03654746, AZD5213, and GSK239512 distribution investigation after oral administration. H$_3$ heteroreceptors modulate acetylcholine levels in cortical regions of the brain, a fact that suggests potential for H$_3$ receptor blockade in reversing scopolamine-induced cognitive deficits. This was investigated in small acute clinical study, where 28 individuals completed a double-blind, placebo-controlled, five-period crossover study, and cognitive function was assessed using the Groton Maze Learning Task as the primary outcome measure. Interestingly, although these primary end points were not met at the extended time point (up to 12 hours), administration of either MK-3134 or donepezil improved performance at the 2-hour time point compared with scopolamine alone. Moreover, it appeared that the combination of MK-3134 and donepezil suppressed the scopolamine negative effect to a greater extent than either drug alone (Cho et al., 2011). Further clinical trials have been completed, focused on evaluation of the efficacy and safety of GSK239512 in Alzheimer’s disease, using a randomized, double-blind, placebo-controlled study and cognitive impairment in schizophrenia. The initial report showed that GSK239512 displayed appropriate tolerability up to a maximum dose of 80 mg/day in patients with Alzheimer’s disease, with some preliminary evidence for positive effects on attention and memory with modest effect sizes (Nathan et al., 2013). A larger follow study (over 190 mild/moderate Alzheimer’s cases) reported GSK239512, up-titrated over 4 weeks (10–20–40–80 µg) followed by a 12-week maintenance phase, compared with sham controls, although it did not display improvement in working memory and other cognitive outcomes, however, it exhibited improved episodic memory, with a reasonable safety profile (Grove et al., 2014). Further large trials are required to investigate this differential responsiveness. A number of reports studying H$_3$ receptor inverse agonists have indicated potential in vivo for anticonvulsant activity utilizing various models, including the maximal electroshock-induced and pentyleneetetrazole-kindled seizure models in rodents (Sadek et al., 2014a,b).

In a randomized multicenter, double-blind, placebo- and active-controlled. parallel group study on adult attention-deficit hyperactivity syndrome on bavisant (JNJ-31001074), the drug did not differ from placebo, whereas atomoxetine hydrochloride and osmotic release oral system methylphenidate were effective (Weisler et al., 2012). A clinical trial with the same drug was also listed at clinicaltrials.gov but the trial has not been initiated. Thus, this indication for which there is experimental support from rodent studies and several drug candidates tested for safety and side effects in humans has not been tested. In a randomized crossover study the H$_3$ receptor inverse agonist MK-0249 was not superior to placebo for the treatment of cognitive impairment in patients with schizophrenia (Egan et al., 2013). In conclusion, the expectations for extensive clinical use of H$_3$ receptor inverse agonists have yet to be realized.

Peripheral indications have also been explored. In combination with fexofenadine, single doses of PF-03654746 produced a reduction in allergen-induced nasal symptoms in a small 20 patient trial using an acute nasal allergen challenge with a bolus of ragweed (Stokes et al., 2012).

V. Histamine H$_4$ Receptor

The H$_4$ receptor is the most recently discovered histamine receptor. The cloning of the H$_3$ receptor provided a template for the search of other histamine receptors. This culminated with six independent groups reporting the cloning of the H$_4$ receptor (Nakamura et al., 2000; Oda et al., 2000; Liu et al., 2001a; Morse et al., 2001; Nguyen et al., 2001; Zhu et al., 2001; O’Reilly et al., 2002). Since that time much research has focused on characterizing the receptor’s role in inflammatory process, because it originally appeared to be predominantly expressed in hematopoietic cells.

A. Receptor Structure

The H$_4$ receptor displays similarities to the H$_3$ receptor in terms of gene and protein secondary structure (Coge et al., 2001a,b). The human H$_4$
Histamine Receptors

631

receptor gene is present as a single copy per haploid genome on chromosome 18q11.2, spans more than 21 kbp, and contains three exons together with two large introns (7867 and >17,500 bp). The coding regions encode amino acids 1–65, 66–119, and 120–390, respectively. The transcript size of the gene is approximately 3.7 or 4.5 kb, which is explained by at least two polyadenylation sites 0.8 kb apart (Coge et al., 2001b). The open reading frame (1172 bp) encodes a 390-amino-acid polypeptide that forms the classic 7-transmembrane structure of the family A rhodopsin-like GPCR. A series of polymorphisms have been identified and confirmed by SNP analysis involving Caucasian, Chinese, Japanese, African-American, and Sub-Saharan African individuals, including V138A and R206H. The occurrence of A138 or H206 is 10-fold higher than the V138 or R206 version, respectively. Further SNPs have been found in intron 1, 33 in intron 2, and 13 in the 3′-untranslated region, as well as a frame-shift at the C terminus of the protein (http://www.ncbi.nlm.nih.gov/SNP).

It is possible that the H4 receptor can exist in dimeric or oligomeric forms. Based on immunoblotting techniques, various structural forms of the H4 receptor have been reported: 44 kDa (unglycosylated monomer), 46 kDa (glycosylated monomer), 85 kDa (glycosylated dimer), and >250 kDa (oligomeric structures) (Nguyen et al., 2001; van Rijn et al., 2006). Based on biochemical (immobilized metal affinity chromatography) and biophysical techniques (time-resolved fluorescence resonance transfer and BRET) in transfected cells, the human H4 receptor can exist as dimeric or oligomeric species (van Rijn et al., 2006). However given the uncertainties around the selectivity of H4 receptor antibodies (see section V.C) and lack of direct evidence in primary cells, it is still uncertain as to whether oligomerization occurs in native tissues and cells or whether it has physiologic consequences.

In addition to this, two human H4 receptor isoforms have been identified and designated H4 receptor 302 and H4 receptor 67, the former lacking residues 68–155, whereas the latter is prematurely terminated at residue 67. These isoforms are the result of alternative splicing, but do not bind histamine or inverse agonists. The occurrence of A138 or H206 is 10-fold higher than the V138 or R206 version, respectively. Further SNPs have been found in intron 1, 33 in intron 2, and 13 in the 3′-untranslated region, as well as a frame-shift at the C terminus of the protein (http://www.ncbi.nlm.nih.gov/SNP).

It is possible that the H4 receptor can exist in dimeric or oligomeric forms. Based on immunoblotting techniques, various structural forms of the H4 receptor have been reported: 44 kDa (unglycosylated monomer), 46 kDa (glycosylated monomer), 85 kDa (glycosylated dimer), and >250 kDa (oligomeric structures) (Nguyen et al., 2001; van Rijn et al., 2006). Based on biochemical (immobilized metal affinity chromatography) and biophysical techniques (time-resolved fluorescence resonance transfer and BRET) in transfected cells, the human H4 receptor can exist as dimeric or oligomeric species (van Rijn et al., 2006). However given the uncertainties around the selectivity of H4 receptor antibodies (see section V.C) and lack of direct evidence in primary cells, it is still uncertain as to whether oligomerization occurs in native tissues and cells or whether it has physiologic consequences.

In addition to this, two human H4 receptor isoforms have been identified and designated H4 receptor 302 and H4 receptor 67, the former lacking residues 68–155, whereas the latter is prematurely terminated at residue 67. These isoforms are the result of alternative splicing, but do not bind histamine or inverse agonists. In heterologous expression systems, these isoforms show pronounced differences between species orthologs, more distal reporter gene assays revealed less pronounced differences. Species splice isoforms have yet to be reported.

The H4 receptor possesses the prototypical acidic residue (Asp943.32) in TM3, which interacts with the amine group of histamine (1, Fig. 3). In addition to the conserved aspartate, a glutamate residue is also present in TM5 (Glu 1825.46), consistent with the H3 receptor, and is another key histamine binding residue (Shin et al., 2002; Uveges et al., 2002). As discussed previously for the H3 receptor, the interaction of the imidazole ring with this glutamate residue is most likely responsible for the relatively high affinity of the H4 receptor for histamine. This amino acid is also important in binding smaller agonist ligands (e.g., VUF8430) (Lim et al., 2008). The H4 receptor also possesses cysteine residues that potentially form disulfide bridges spanning TM3 and ECL2. Interestingly, using a chimeric and site-directed mutagenesis approach it was shown that the ECL2 loop is also involved in the binding pocket. Phe169 in ECL2 was identified as the single amino acid responsible for the differences in histamine affinity between the human and rodent H4 receptor (Lim et al., 2008). Final confirmation of this suggestion awaits successful crystallization.

Interestingly, the H4 receptor does not contain the so-called “ionic lock” between the highly conserved R3.50 of the DRY motif at the end of TM3 and a negative charged D/E6.30 in TM6, which in many GPCRs is considered to hold the receptor in an inactive state (Smit et al., 2007). Yet, the H4 receptor contains an alanine residue at position 6.30, and mutation of this residue (e.g., into glutamate) does not really alter the constitutive signaling (Schneider et al., 2010a). A
pseudoionic lock has been claimed for differentiating (partial) agonist from antagonist binding modes (Werner et al., 2010).

### B. Signal Transduction Mechanisms

A detailed understanding of signal transduction mechanisms downstream of H₄ receptor activation is emerging. Like the structurally related H₃ receptor, the H₄ receptor belongs to the class of G₁/G₂-coupled GPCRs. The primary second messenger appears to be increased intracellular Ca²⁺ (Raible et al., 1994; Buckland et al., 2003; Hofstra et al., 2003; Dijkstra et al., 2007; Jemima et al., 2014), although activation of kinases has also been reported (Gutzmer et al., 2005, 2009; Desai and Thurmond, 2011; Ferreira et al., 2012; Mompert et al., 2012; Karlstedt et al., 2013). The best studied native cell type that expresses the H₄ receptor is the human eosinophil. The H₄ receptor-mediated activity in these cells such as cell shape change, Ca²⁺ mobilization, and actin polymerization is sensitive to inhibition by the Gα₁/Gα₂-ADP-riboseylating toxin pertussis toxin (Raible et al., 1994). Along the same lines, H₄ receptor-mediated Ca²⁺ mobilization in mouse bone marrow–derived mast cells is also pertussis toxin sensitive (Hofstra et al., 2003). The pertussis toxin data suggest that the H₄ receptor couples to Gα₁ or Gα₂-subunits; however, because myeloid cells express Gα₁-subunits (predominantly Gα₁2 and, to a lesser extent, Gα₁3, but not Gα₁1) and do not express Gα₂-subunits (Birnbaumer, 2007), it is very likely that Gα₁2-and Gα₁3 G protein α-subunits represent the cognate coupling partners of the H₄ receptor in these native cells (Fig. 4).

Transfected cell systems also support the conclusion that the H₄ receptor is a G₁-coupled GPCR. Expression of the H₄ receptor in SK-N-MC neuroblastoma cells leads to ligand-dependent inhibition of forskolin-stimulated cAMP accumulation (Nakamura et al., 1994; Oda et al., 2000; Liu et al., 2001a; Lim et al., 2005). The inhibitory effect of the H₄ receptor on cAMP accumulation is pertussis toxin sensitive, indicative for G₁ protein coupling (Oda et al., 2000).

In further support of coupling of the H₄ receptor to Gα₁ proteins, to detect H₄ receptor-mediated Ca²⁺ mobilization in a commonly used mammalian expression system such as HEK293 cells, the H₄ receptor has to be cotransfected with the “universal” G protein G₁5α or G₁6α (Oda et al., 2000) or a chimeric Gα₁ protein in which the last five C-terminal amino acids are replaced by those of Gα₁/Gα₂-subunits (Coward et al., 1999; Liu et al., 2001a; Morse et al., 2001; Zhu et al., 2001; Jiang et al., 2008).

G protein coupling of the H₄ receptor was further analyzed in the SF9 insect cell expression system. One concern of this system is that the receptor expressed in SF9 insect cells may differ from the H₄ receptor expressed in mammalian cells. However, overall, it appears that the H₄ receptor expressed in SF9 insect cells and mammalian cells are similar (Schneider et al., 2009). The human H₄ receptor couples only poorly, if at all, to insect cell G proteins as assessed by GTPγS binding and GTPase activity (Schneider et al., 2010b). Nonetheless, even in the absence of mammalian G proteins, the human H₄ receptor exists in a state that exhibits high agonist affinity. Evidently, because G proteins are not required for this state, high-affinity [³H]histamine binding is GTPγS insensitive. These properties of the human H₄ receptor are in marked contrast to several other G₁-coupled receptors, including the formyl peptide receptor that, like the H₄ receptor, is expressed in myeloid cells (Ye et al., 2009). Moreover, GTPγS-insensitive [³H]histamine binding to the H₄ receptor has also been observed for the H₄ receptor expressed in mammalian cells (Lim et al., 2010). The lack of interaction with endogenous insect G proteins makes this an excellent system for exploring the interaction with mammalian G proteins. When reconstituted with various G protein α-subunits and the Gα₁₁α₂-complex, human H₄ receptor exhibits clear preference for Gα₁₁ (Schneider et al., 2009, 2010a), which is consistent with the fact that this is the most likely partner in eosinophils and mast cells. There is some coupling to Gα₁ and Gα₃, suggesting that these subunits may also be important in some cell types. However, the coupling to Gα₁, a G protein α-subunit predominantly expressed in neuronal and neuroendocrine cells (Birnbaumer, 2007), is poor (Schneider et al., 2009).

The human H₄ receptor coupled to Gα₁₁ exhibits high constitutive activity as is evident by high basal GTPγS binding and GTPase activity, relatively small agonist effects on guanine nucleotide exchange, and profound inhibitory effects of the inverse agonist thioperamide (Schneider et al., 2009). Amino acids F169 and S179 appear to play key roles for this high constitutive activity of the human H₄ receptor (Wifling et al., 2015). Because the human H₄ receptor exhibits high constitutive activity (Lim et al., 2005; Schneider et al., 2010b), H₄ receptor agonists decrease cAMP accumulation, whereas H₄ receptor inverse agonists increase cAMP accumulation (Lim et al., 2005; Kottke et al., 2011). In marked contrast to the situation with recombinant systems, there is little, if any, evidence as yet for constitutive activity of the H₄ receptor in native systems.

In primary cells, it appears that the H₄ receptor mediates signaling via increases in calcium (Raible et al., 1994; Buckland et al., 2003; Hofstra et al., 2003; Dijkstra et al., 2007; Jemima et al., 2014). In addition kinases such as ERK, phosphoinositide 3-kinase (PI3K), and p38 and the transcription factor activating protein-1 have been shown to be activated by the H₄ receptor (Gutzmer et al., 2005, 2009; Desai and Thurmond, 2011; Ferreira et al., 2012; Mompert et al., 2012; Karlstedt et al., 2013).

The different H₄ receptor species orthologs exhibit different pharmacological properties, perhaps related to a relatively low level of homology (Liu et al., 2001b;
Jiang et al., 2008). For example, the affinity of histamine and various other ligands vary between the species. In addition, studies measuring inhibition of cAMP-dependent reporter gene expression and chimeric G protein–mediated increases in cytosolic calcium ion concentration or reporter gene expression indicated that not only the human H4 receptor, but also canine, murine, rat, and guinea pig H4 receptors couple to G1 proteins (Liu et al., 2001b; Jiang et al., 2008). In SF9 cells, human, canine, rat, and murine H4 receptor all couple to G1 proteins as assessed by agonist-stimulated GTP hydrolysis (Schnell et al., 2011). These studies confirmed the previously observed pharmacological differences between H4 receptor species orthologs and also revealed substantial differences in constitutive activity of the four species orthologs. Specifically, only human H4 receptors, but not canine and murine H4 receptors, possess high constitutive activity as assessed by inhibitory effects of thioperamide on basal GTP stimulation (Schnell et al., 2011). These studies confirmed the previously observed pharmacological differences between H4 receptor species orthologs and also revealed substantial differences in constitutive activity of the four species orthologs. Specifically, only human H4 receptors, but not canine and murine H4 receptors, possess high constitutive activity as assessed by inhibitory effects of thioperamide on basal GTP hydrolysis (Schnell et al., 2011).

C. Anatomic Framework

Identification of the expression pattern of the H4 receptor has been hampered by several issues. mRNA levels can be used to determine if the H4 receptor message is expressed in a cell type or tissue; however, it does not provide evidence that the protein is expressed. Furthermore, it can be difficult to determine exactly which cell types express the RNA in tissues, and the purity level of primary cells can lead to false positive signals. Finally, the expression of RNA may depend on the environment, because it is known that message levels and activity change in response to inflammatory stimuli and to the state of the cell. For example, the H4 receptor was undetectable on human CD8+ T cells in one report (Ling et al., 2004), whereas another (Gantner et al., 2002) showed a function for the receptor in these cells by pharmacological means and mRNA expression; however, the level of expression varied from donor to donor. A major issue is the lack of a widely accepted and available antibody specific for the receptor. In particular the selectivity of the available antibodies has been questioned and care should be taken with interpreting expression data based on these antibodies. Specifically, one study (Beermann et al., 2012b), using stringent controls, showed that three commercially available antibodies directed against the human and mouse H4 receptor do not specifically recognize the H4 receptor in various receptor formats, including fluorescence-activated cell sorting and immunoblotting. This study included controls with epitope-tagged H4 receptors and H4 receptor knockout cells and is in line with a series of previous studies on various biogenic amine GPCRs indicating that many GPCR antibodies distributed commercially do not fulfill the criteria necessary for receptor expression studies (Michel et al., 2009). A general caveat for H4 receptor work, or any other field for that matter, is that one cannot rely solely on mRNA data, antibody data, or pharmacology data with a single ligand to prove the existence of the receptor. The best approach currently is to use a combination of techniques with the definitive answer being given by pharmacological activities defined by multiple ligands.

One of the best examples of using pharmacology to define the receptor function comes from the early work with eosinophils. In the late 1970s it was noted that histamine could induce eosinophil chemotaxis via non-H1 receptor, non-H2 receptor (Clark et al., 1975, 1977; Wadee et al., 1980). Later it was discovered that histamine-stimulated increases in intracellular Ca2+ in eosinophils were blocked by thioperamide, impromidine, and burimamide, but not by pyrilamine or cimetidine, suggesting at the time that the effects of histamine were H3 receptor mediated (Raible et al., 1994). However, other data did not match the known pharmacology of the H3 receptor, including the fact that (R)-α-methylhistamine was over an order of magnitude less potent than histamine. The cloning of the H4 receptor and its pharmacological characterization indicated that this pharmacology matched that of the new receptor and it was subsequently shown that indeed the H4 receptor mediates Ca2+ responses and chemotaxis of eosinophils (Buckland et al., 2003; Ling et al., 2004).

At the mRNA level, the H4 receptor appears to be most strongly expressed in bone marrow, but expression can also be detected in peripheral blood, spleen, thymus, as well as in lung, small intestine, colon, and heart (Nakamura et al., 2000; Oda et al., 2000; Liu et al., 2001a; Morse et al., 2001; Nguyen et al., 2001; Zhu et al., 2001). Some have also indicated H4 receptor expression in liver, brain, skeletal muscle, gastrointestinal tract, and epidermal tissue (Nakamura et al., 2000; Coge et al., 2001b; O’Reilly et al., 2002; Buckland et al., 2003; Sander et al., 2006; Rossbach et al., 2009, 2011; Yamaura et al., 2009). However, these organs also contain, to different extents, hematopoietic cells that may account for the mRNA signals. H4 receptor expression has been detected in synovial cells from rheumatoid arthritis and osteoarthritis patients and localized to both fibroblast-like and macrophage-like cells from rheumatoid arthritis synovial tissue, but this expression has not been confirmed by any functional data (Ikawa et al., 2005; Ohki et al., 2007; Grzybowska-Kowalczyk et al., 2008). The exact details of the expression of the receptor are still emerging and are complicated by the fact that the receptor levels and activity change in response to inflammatory stimuli and to the state of the cell. Furthermore, there is evidence that the receptor can be upregulated by inflammatory stimuli. For example, it was shown that the receptor expression on monocytes could be upregulated by interferon (IFN) γ treatment and that interleukin (IL)-4 upregulated the receptor expression on T cells (Dijkstra et al., 2007; Gutzmer et al., 2009). In addition it has been shown that the receptor is upregulated in all peripheral
organs 24 hours after inducing sepsis in a mouse model and in the kidney of diabetic rats (Matsuda et al., 2010; Rosa et al., 2013).

Expression coupled with function defined by pharmacological methods has been shown on mast cells; eosinophils; neutrophils; dendritic cells; Langerhans cells; natural killer cells; monocytes; T cells; including γδ T cells, T helper 1, 2, and 17 cells; keratinocytes; inflammatory dendritic epidermal cells; and fibroblasts (Gantner et al., 2002; Hofstra et al., 2003; Ling et al., 2004; Lippert et al., 2004; Gutzmer et al., 2005, 2009; Sander et al., 2006; Damaj et al., 2007; Dijkstra et al., 2007, 2008; Godot et al., 2007; Bäumer et al., 2008; Ikawa et al., 2008; Yamaura et al., 2009; Gschwandtner et al., 2010, 2011, 2012, 2013; Truta-Feles et al., 2010; Mommer et al., 2012; Glatzer et al., 2013; Mirzahosseini et al., 2013; Cowden et al., 2014; Czerner et al., 2014; Dib et al., 2014; Jemima et al., 2014). In addition, expression data, but as to date no functional data, have been reported in epithelial cells and basophils (Hofstra et al., 2003; Sander et al., 2006). However, care must be taken in interpreting all of these data even where expression appears to correlate with pharmacological activity. For example, some groups report mRNA in monocytes and CD8* T cells whereas others do not, which may be attributed to intrasubject variability in expression or in different cell isolation and detection methods used (Gantner et al., 2002; Ling et al., 2004; Dijkstra et al., 2007; Werner et al., 2014). In addition, although most of the pharmacological data are compelling, some details require further scrutiny. For example, potency of thioperamide reported by Damaj et al. (2007) for natural killer cells and monocyte-derived dendritic cells is higher than that expected from binding data in recombinant systems (Liu et al., 2001a). A similar observation can be noted in the inhibition of CCL2 secretion in human monocytes, where the potency of clobenpropit is much higher than histamine in contrast to the affinity data in recombinant systems (Liu et al., 2001a; Dijkstra et al., 2007). These issues are clearly highlighted in the work of Gschwandtner et al. (2013) where six different H4 receptor agonists were shown to inhibit IL12p70 production in human monocytes, but in most cases this was only partially blocked by an H4 receptor antagonist. The situation is not as clear-cut as it first seems and warrants further investigation.

Recent studies provided evidence that genetic variations of the H4 receptor are associated with inflammatory diseases. Certain polymorphisms of the human H4 receptor gene that should result in an increased expression or signaling of the receptor were associated with atopic dermatitis (Yu et al., 2010b). Along this line, keratinocytes derived from patients with atopic dermatitis expressed higher levels of the H4 receptor mRNA compared with keratinocytes from patients without skin disease or psoriasis (Glatzer et al., 2013). In asthma, there appeared to be a link between three single nucleotide polymorphisms in the H4 receptor gene and infection-induced asthma (Simon et al., 2012). mRNA encoding the H4 receptor was significantly higher expressed and H4 receptor gene copy numbers were significantly amplified in patients with systemic lupus erythematosus compared with healthy controls. Moreover, H4 receptor gene copy numbers correlated to the incidence of arthritis, proteinuria, and antinuclear antibody abnormalities in systemic lupus erythematosus (Yu et al., 2010a).

There is some evidence that the H4 receptor may be expressed in the nervous system, but this remains controversial and needs further research. In general, results obtained with antibodies have not always been verified with parallel analyses of mRNA expression, and there is currently no consensus about expression of H4 receptor in various parts of the nervous system. In the human brain, expression of H4 receptor mRNA has been reported in the amygdala, cerebellum, corpus callosum, cortex frontal cortex, hippocampus, and thalamus in samples of a commercial mRNA panel (Strakhova et al., 2009b). Immunohistochemistry suggested that lamina I–VI of the murine and human cerebral cortex may express the H4 receptor with the strongest expression in layers IV and VI for the latter (Connelly et al., 2009). Expression has also been reported in the murine hippocampus, granule cell layer of the cerebellum, the thalamus, and in the spinal cord (Connelly et al., 2009; Strakhova et al., 2009b). The expression pattern in mouse and rat brains appeared to be similar to that in humans. However, quantitative reverse-transcription polymerase chain reaction and in situ hybridization data from many mammalian CNS areas are still not available to support the findings. In the rat, expression of the H4 receptor by immunohistochemistry was detected in approximately one-third of dorsal root ganglion neurons of all size classes. Immunoreactivity was also present in laminae I, II, and IV in spinal cord, in a pattern consistent with expression on primary afferent terminals (Strakhova et al., 2009b).

mRNA expression of both the full-length H4 receptor and one of the deletion forms has also been detected in a rat brain endothelial cell line using reverse-transcription polymerase chain reaction and sequencing (Karlstedt et al., 2013). The H4 receptor may also be involved in the vestibular system, because expression of the receptor has been reported in vestibular nucleus neurons and ganglia in rats (Desmadryl et al., 2012; Zhang et al., 2013). Overall, the presence of the H4 receptor in afferent pathways including dorsal root ganglion, spinal cord dorsal horn, and thalamus, as well as in other CNS areas, appears to be entirely consistent with a role in sensory signaling. The identity of the H4R-expressing sensory neurons in humans is yet to be established, but expression on skin innervating
sensory neurons was shown in mice (Rossbach et al., 2011).

D. Function

One of the first functions ascribed to the H4 receptor was in mediating chemotaxis. Histamine acting via the H4 receptor has been shown to induce chemotaxis of a number of different cell types. In mast cells, histamine was shown to induce chemotaxis, and these effects were abrogated by treatment with H4 receptor antagonists but not antagonists to the other histamine receptors (Hofstra et al., 2003; Thurmond et al., 2004). Furthermore, neither response was seen in mast cells from H4R-deficient mice. Histamine also enhanced mast cell precursor chemotaxis to CXCL12 via a priming effect, but not to stem cell factor or leukotriene B4 (Godot et al., 2007). This enhanced chemotaxis was blocked by H4 receptor antagonists, but not antagonists for the H1 receptor or H2 receptor. In eosinophils, histamine or H4 receptor agonists induced chemotaxis, cell shape change, actin polymerization, and synergized with other chemotactic agents (O’Reilly et al., 2002; Buckland et al., 2003; Ling et al., 2004; Lim et al., 2005; Yu et al., 2010c). Furthermore, histamine activation of the H4 receptor induced adhesion molecule upregulation in eosinophils (Buckland et al., 2003; Ling et al., 2004).

However, compared with eosinoid and formyl peptides, the stimulatory effects of histamine on eosinophil chemotaxis are small (Reher et al., 2012). Moreover, in contrast to the formyl peptide receptor, the H4 receptor does not mediate reactive oxygen species formation or eosinophil peroxidase release (Reher et al., 2012). Dendritic cells migration can also be modulated by the H4 receptor (Gutzmer et al., 2005; Damaj et al., 2007; Bäumer et al., 2008; Gschwandtner et al., 2010). Histamine-induced migration of dendritic cells in vitro or ex vivo and a H4R-dependent migration of dendritic cells was detected in vivo in mice during an allergic response (Cowden et al., 2010b). The migration of Langerhans cells has also been shown to be mediated by the H4 receptor (Gschwandtner et al., 2010). An ex vivo assay was used to show that the H4 receptor could mediate chemotaxis of Langerhans cells from epidermis from healthy donors or patients with bullous pemphigoid (Gschwandtner et al., 2010). In mice, injection of an H4 receptor agonist induced the migration of Langerhans cells in vivo (Gschwandtner et al., 2010). Chemotaxis of monocytes, γδ T cells, and fibroblasts has also been shown to be mediated via the H4 receptor (Damaj et al., 2007; Kohyama et al., 2010; Truta-Feles et al., 2010), although it was criticized (in particular for monocytes) that these data have only been published in single studies and have not been confirmed by other groups (Werner et al., 2014).

Migration of cells in response to H4 receptor stimulation has also been demonstrated in animal models or inflammation. The role of H1 receptor and H4 receptor in an ovalbumin specific murine dermatitis model was investigated with the adoptive transfer of ovalbumin-specific Th2-cells (Mahapatra et al., 2014). Treatment of recipient mice with either H1 receptor or H4 receptor antagonists resulted in a reduced migration of Th2 cells to sites of allergen challenge. Cytokine production in skin draining lymph nodes was only reduced by combined application of H1 receptor and H4 receptor antagonist, whereas mast cell counts were not altered by either H1 receptor, H4 receptor, or combined blockade. The paper does not state any results with regard to the effect of H1 receptor or H4 receptor blockade on skin inflammation.

Another study investigated carrageenan-induced pleurisy in mice (Ahmad et al., 2014). The administration of JNJ-7777120 (58) 1 hour before carrageenan application decreased both the number of T-cell subsets and GITR(+), GITR(+) IL-17A(+) expressing T cells, and the production of Th1/Th17 cytokines, whereas the administration of 4-methylhistamine (17) increased both the numbers of CD4(+), CD25(+), CD4(+) CD25(+), GITR(+), GITR(+) IL-17A(+) expressing T cells and the levels of T helper type 1 (Th1/Th17 cytokines. JNJ-7777120 had anti-inflammatory effects, whereas 4-methylhistamine worsened inflammation in this model.

In addition to chemotaxis, the H4 receptor is also involved in cytokine release from a number of cell types. It has been shown that histamine can induce IL-16 production from CD8+ T cells (Gantner et al., 2002). This can be blocked by H2 receptor or H4 receptor antagonists but not by antagonists of the H1 receptor. The H4 receptor inhibited IL-12p70 release from human monocyte-derived dendritic cells and inflammatory dendritic epidermal cells (Gutzmer et al., 2005; Dijkstra et al., 2008). In mouse dendritic cells, Toll-like receptor (TLR)–stimulated production of IL-6, KC, MIP-1α, interferon-γ–induced protein 10 (IP-10), and tumor necrosis factor α (TNFα) was blocked by an H4 receptor antagonist and was attenuated in dendritic cells from H4R-deficient mice; however, in this case, IL-10 and IL-12p70 were unchanged (Dunford et al., 2006). Regulation of cytokine production from dendritic cells appears to impact their ability to polarize CD4+ T cells to a Th2 phenotype, and histamine acting via the H4 receptor may also mediate cross-presentation to CD8+ T cells (Dunford et al., 2006; Amaral et al., 2007). Histamine downregulated the production of CCL2 in human monocytes, Langerhans cells, inflammatory dendritic epidermal cells, and slan-dendritic cells (Dijkstra et al., 2007, 2008; Gschwandtner et al., 2011, 2012). Furthermore, other Th1-promoting cytokines and chemokines were downregulated in a variety of human antigen-presenting cells via H4 receptor stimulation, such as downregulation of TNFα, interferon α, and CXCL8 on plasmacytoid dendritic cells (Gschwandtner et al., 2011, 2012), and IP-10 on monocytes and myeloid dendritic cells (Glatzer et al., 2014). Stimulation of the H4 receptor
induced IL-31 production in peripheral blood mononuclear cells (PBMC) or Th2 polarized T cells, and this production was significantly increased in PBMC from subjects with atopic dermatitis compared with healthy controls (Gutzmer et al., 2009). The receptor also mediated IL-4 and IFNγ production from murine natural killer T cells in vivo (Leite-de-Moraes et al., 2009). Cytokine and chemokine production in vivo has also been shown to be regulated by the H4 receptor in several disease models. Reduction in Th2 cytokines such as IL-4, IL-5, and IL-13 levels were observed after H4 receptor antagonist treatment in mouse models of asthma, allergic rhinitis, and allergic contact dermatitis (Takahashi et al., 2009; Cowden et al., 2010a; Seike et al., 2010). H4 receptor antagonist treatment reduced tissue TNFα levels in a rat colitis model, and several inflammatory cytokines and chemokines were reduced in a model of Th2-dependent dermal inflammation (Varga et al., 2005; Cowden et al., 2010a). IFNγ synthesis of murine T helper cells was also reduced by the H4 receptor antagonist (Vauth et al., 2012). The levels of lipid mediators are also affected by the H4 receptor, with antagonists showing reduction in leukotriene B4 and prostaglandin D2 in models of pleurisy and peritonitis, respectively (Takeshita et al., 2003; Strakhova et al., 2009a).

The H4 receptor also appears to be involved in IL-17 production from Th17 cells. Histamine and an H4R-selective agonist increased IL-17 message and protein secretion from human Th17 cells, and this effect could be blocked by an H4 receptor antagonist (Momment et al., 2012). It has also been shown that H4 receptor antagonists can reduce IL-17 production from PBMC (peripheral blood mononuclear cells) after stimulation (Cowden et al., 2014). The same effect is seen in mice. Stimulation of whole blood with anti-CD3/CD28 and IL-23 led to an increase in IL-17 production in vitro, and this was decreased in blood taken from H4R-deficient mice or mice treated with an H4 receptor antagonist (Cowden et al., 2014). Furthermore, it was shown that Th17 cell development in vivo was inhibited in H4R-deficient mice or mice treated with an H4 receptor antagonist (Cowden et al., 2014). Finally, a reduction in IL-17 levels via H4 receptor blockade has been noted in mouse models of asthma, dermatitis, and arthritis (Dunford et al., 2006; Cowden et al., 2010b, 2014). Basophils have been implicated in enhancing Th17 responses in humans, and this effect appears to be mediated by H2 receptor and H4 receptor (Wakahara et al., 2012). In human neutrophils, engagement of the H4 receptor blocked the adhesion-dependent degranulation, indicating a possible anti-inflammatory effect of the H4 receptor on these cells (Dib et al., 2014).

In human and murine mast cells, the H4 receptor is not only involved in chemotaxis but also in other functions. H4 receptor stimulation in murine bone marrow–derived mast cells induced IL-6 production and increased lipopolysaccharide (LPS)-induced IL-6 production via ERK and PI3K activation (Desai and Thurmond, 2011). Stimulation of murine bone marrow–derived mast cells with an H4 receptor antagonist during the IgE sensitization phase inhibited the degranulation and IgE-induced upregulation of the high affinity IgE receptor FceRI (Mirzahosseini et al., 2013). In human cord blood–derived mast cells, histamine and 4-methylhistamine (17) induced degranulation and the production of leukotrienes, and these effects were blocked by JNJ-7777120 (58) (Jiménez et al., 2014). Furthermore, these cells responded to 4-methylhistamine with ERK and PI3K activation as well as the production of a variety of inflammatory mediators such as IL-6 (Jiménez et al., 2014). In ex vivo animal models, human mastocytoma cells and bone marrow–derived murine mast cells, H4 receptor activation resulted in inhibition of renin release via activation of protein kinase C isotype-ε and aldehyde dehydrogenase type-2 (Aldi et al., 2014).

The in vitro effects on chemotaxis and mediator release from immune cells suggest that the H4 receptor should be involved in inflammatory responses. Indeed this has been borne out in several animal models. The first in vivo reports of H4 receptor activity involved neutrophilia models induced by the TLR ligand zymosan where H4 receptor activity was shown to be anti-inflammatory (Gantner et al., 2002; Thurmond et al., 2004). Effects on neutrophils can also be seen in a rat colitis model where treatment with H4 receptor antagonists reduced tissue damage, neutrophilia, and tissue TNFα levels (Pogel et al., 2005; Varga et al., 2005). Treatment with JNJ-7777120 was protective in a model of gastric ulceration (Adami et al., 2012). A link between TLR signaling and the H4 receptor may be a general effect as TNF production upon in vivo administration of LPS has been shown to be reduced in H4R-deficient mice or upon treatment with H4 receptor antagonists (Cowden et al., 2013). The role of the H4 receptor in both innate and adaptive immune responses may explain the protective effect of H4 receptor antagonists or genetic deficiency in the receptor in mouse models of arthritis (Nent et al., 2013; Cowden et al., 2014).

Eosinophilic inflammation appears also to be mediated by the H4 receptor. In mouse models of asthma, H4 receptor antagonists reduced eosinophilia and Th2 responses (Dunford et al., 2006; Deml et al., 2009; Cowden et al., 2010a; Somma et al., 2013). However, the story may not be as straightforward as it first appeared, because a locally administered H4R/H2 receptor agonist was protective in another mouse asthma study and these effects may have been mediated via enhanced recruitment of regulatory T cells via the H4 receptor (Morgan et al., 2007). In another study on EAE, H4 receptor knockout mice had a worse outcome compared with wild-type controls. This was attributed to altered migration and function of regulatory T cells in the H4 receptor knockouts (del Rio et al., 2012). Th2
responses can also be impacted in models of cutaneous inflammation. In most acute models driven by hapten application, the H4 receptor clearly mediated pruritic responses but did not have a role in the acute inflammation (Rossbach et al., 2009; Seike et al., 2010). However, with chronic application the situation appears to change and an H4 receptor antagonist was anti-inflammatory, whereas an H4 receptor agonist was pro-inflammatory (Seike et al., 2010). This may be a result of the switch to a more eosinophilic inflammation with the chronic treatment. Interestingly, the one acute hapten model that is sensitive to H4 receptor inhibition is the one where even the acute inflammation has a strong eosinophilic component. In this case, treatment with H4 receptor antagonists were anti-inflammatory and led to a reduction in the number of mast cells and eosinophils in the affected skin (Cowden et al., 2010b). In addition to effects on eosinophils, the H4 receptor also mediates keratinocyte proliferation, which may explain some of the effects seen in the model (Glatzer et al., 2013). Finally, the combination of H1 receptor and H4 receptor antagonists was more effective than either alone in two models of contact dermatitis (Matsushita et al., 2012; Ohsawa and Hirasaawa, 2012).

Beyond the role in inflammatory response the H4 receptor has also been associated with neuronal responses, although this remains controversial (Schneider et al., 2014b). A study analyzed [35S]GTPγS binding and noradrenaline release in human, guinea pig, and mouse cortex (Feliszek et al., 2015). The H4 receptor agonist 4-methylhistamine (17) failed to affect these readouts, whereas the H3 receptor increased [35S]GTPγS binding and inhibited noradrenaline release. These readouts are limited in their coverage of potential neuronal effects of the H4 receptor, and so further studies are required. Nevertheless, the H4 receptor expression has been reported on neurons, suggesting that it can have an effect on sensory signaling. In whole cell clamp recordings of layer IV somatosensory cortex cells from mice, H4 receptor-induced hyperpolarization has been reported with a single H4 receptor agonist, antagonist, and respective dose (Connelly et al., 2009); confirmation is required with multiple ligands and a full concentration range. In rat vestibular neurons, treatment H4 receptor antagonist led to inhibitory effects on the action potential (Desmadryl et al., 2012). In addition it has been shown that the receptor also mediated action potential discharge in human submucosal neurons (Breunig et al., 2007). Single-cell Ca2+ imaging studies in mice recently showed that histamine induces a [Ca2+]i increase in a subset of (skin-specific) sensory neurons via activation of the H4 receptor. Dual activation of H1 receptor and H4 receptor on sensory neurons, which in turn results in the excitation of histamine-sensitive afferents, may underlie the sensation of itch (Rossbach et al., 2011). These effects may translate into the nociceptive and antipruritic activities seen in animal models (Bell et al., 2004; Coruzzi et al., 2007; Dunford et al., 2007; Altenbach et al., 2008; Cowart et al., 2008; Nakano et al., 2009; Rossbach et al., 2009; Yamaura et al., 2009; Cowden et al., 2010b; Hsieh et al., 2010a,b). In both cases the effects of H4 receptor antagonists appear to be mediated via modulation of neuronal activity. For example, the reduction in pruritic responses in H4R-deficient mice could not be reconstituted with bone marrow from wild-type animals (Dunford et al., 2007). Furthermore, compound 48/80 was shown to induce pruritic responses by directly activating neurons, and these effects were reduced by H4 receptor antagonists (Dunford et al., 2007).

Recently, the expression of all four histamine receptors has been demonstrated on microglia, which represents resident immune cells in the brain (Ferreira et al., 2012; Dong et al., 2014). Histamine induced microglia migration and inhibited LPS-induced IL-1β production via the H4 receptor in one study (Ferreira et al., 2012). In another study, histamine induced TNFα and IL-6 production, which could be blocked by H1 receptor and H4 receptor antagonists (Dong et al., 2014). Thus, neuronal functions could also be indirectly affected via histamine influence on microglia.

A number of other functions have been described for the H4 receptor. One study showed that the administration of histamine increased COX-2 expression and activity, cell proliferation, and vascular endothelial growth factor production in the COX-2-positive colon cancer cell lines HT29 and Caco-2, and treatment with the H2 receptor or H4 receptor antagonists prevented these effects (Cianchi et al., 2005). The H4 receptor has been shown to mediate cell cycle arrest in hematopoietic progenitor cells induced by growth factors (Petit-Bertron et al., 2009). In addition, activation of the receptor appears to inhibit proliferation of several human cancer cell lines (Massari et al., 2011, 2013). The release of adrenocorticotropic hormone from a mouse pituitary tumor cell line via H4 receptor activation has also been reported (Meng et al., 2008). Simultaneous activation of H4 receptor and H2 receptor has been reported to mediate sickle erythrocyte adhesion to endothelium (Wagner et al., 2006).

In a rat model of postinflammatory visceral hypersensitivity, colitis was induced by trinitrobenzenesulfonic acid, and after healing, visceral sensitivity was measured after administration of JNJ-7777120 (58) and/or levocetirizine (11) (Deiteren et al., 2014). Visceral sensitivity was reduced by JNJ-7777120 and levocetirizine, the combination of both had a synergistic effect.

**E. H4 Receptor-Selective Ligands**

Many known ligands of the H3 receptor, notably imidazole-containing compounds, also possess significant affinity for the H4 receptor. These include (R)-α-methylhistamine (33), imetit (34), immepip (35), and clobenpropit (41), which all act as agonists at the H4 receptor. In
contrast, the H$_3$ receptor neutral antagonist thioperamide (40) was shown to be an inverse agonist of the H$_4$ receptor (Oda et al., 2000; Liu et al., 2001a,b; Lim et al., 2005).

1. Agonists. The first described H$_4$ receptor agonists were methylcyanoguanidine analogs of 2,5-disubstituted tetrahydrofuranylimidazoles. These compounds have moderate affinity for the H$_4$ receptor and some selectivity over H$_3$ receptor (Lim et al., 2005). The best example is OUP-16, with a binding $K_i$ of 125 nM for the human H$_4$ receptor and an 18-fold selectivity over H$_3$ receptor (Hashimoto et al., 2003).

Although initially developed as a H$_2$ receptor ligand, 4-methylhistamine (17) ($K_i = 50$ nM) is the most selective H$_4$ receptor agonist currently reported, with more than 100-fold selectivity over the H$_1$ receptor, H$_2$ receptor and H$_3$ receptor. Structural modification of dimaprit (a nonimidazole, mixed H$_2$ receptor/H$_3$ receptor/H$_4$ receptor ligand; 19) led to the discovery of VUF-8430 (57), a full agonist at the H$_4$ receptor with around 30-fold selectivity over the H$_3$ receptor (Lim et al., 2006).

The antipsychotic drug clozapine (56) has affinity for a number of GPCRs but also possesses H$_4$ receptor agonist activity. Minor structural modification of this tricyclic compound led to the identification of VUF-6884, a close analog with good affinity for the H$_4$ receptor, shown to be more than 300-fold selective over H$_3$ receptor (Lim et al., 2006). The aminopyrimidine ligand ST-1006 (75) has been characterized as the most potent H$_4$ receptor agonist reported to date, with a PEC$_{50}$ of 8.95 (Gschwandtner et al., 2013) (Fig. 15).

2. Antagonists. The indole carboxamide compound JNJ-7777120 (1-[[5-chloro-1H-indol-2-yl] carbonyl]-4-methylpiperazine; 58) was the first published selective nonimidazole H$_4$ antagonist. It was reported to bind to the human H$_4$ receptor with high affinity ($K_i = 4$ nM) and has excellent selectivity over a panel of GPCRs, including the H$_1$ receptor, H$_2$ receptor and H$_3$ receptor (Thurmond et al., 2004). JNJ-7777120 also possesses high affinity for the mouse and rat H$_4$ receptor (Thurmond et al., 2004), and it has been used extensively as the reference compound to determine the role of H$_4$ receptor antagonism in a variety of experimental animal models of disease (Stark, 2013).

Based on JNJ-7777120, a range of structurally diverse compound classes has evolved, as represented by the benzimidazole VUF-6002, also known as JNJ-10191584 (59) (Terzioğlu et al., 2004), and thienopyrrolole (60) analogs (Venable et al., 2005). Both compounds 59 and 60 demonstrated binding affinities close to that of JNJ-7777120 (Terzioğlu et al., 2004; Venable et al., 2005). Similar compounds were published by Pfizer (New York, NY), as represented by compound 61, where the N-methylpiperazine moiety of 59 was replaced by an octahydropyrrolo[3,4-c]pyrrole group. This compound has low nanomolar affinity for the human H$_4$ receptor (Lane et al., 2012). Further benzimidazole-containing compounds were described in a series of patents from Johnson & Johnson (New Brunswick, NJ) (Arienti et al., 2006; Lee-Dutra et al., 2006; Edwards et al., 2007a,b). The benzimidazole scaffold in these compounds is typically linked to a substituted phenyl or heterocycle. These are then connected by an alkyloxy or alkyl amine chain to a piperidine or (homo)piperazine moiety.

Quinoxaline derivatives such as compound 62 were found to possess excellent affinity for the human H$_4$ receptor (Edwards and Venable, 2005). Further exploration of the SAR led to the identification of piperazin-1-yl quinoxalines, including VUF-10214 (63) and VUF-10148 (64), which retained good H$_4$ receptor potency and demonstrated anti-inflammatory efficacy in a rat model of carrageenan-induced paw edema (Smits et al., 2008).

Aminopyrimidine analogs are the most widely published H$_4$ receptor antagonists and it was Bayer (Leverkusen, North Rhine-Westphalia, Germany) who first disclosed two series of 2-aminopyrimidine compounds possessing significant H$_4$ receptor functional activity, as exemplified by compound 65 (Sato et al., 2005). Subsequently, further 2-aminopyrimidine H$_4$ receptor antagonists were published by Johnson & Johnson (66) (Cai et al., 2008), Pfizer (67) (Bell et al., 2007), Palau (Palau-soleità i Plegamans, Barcelona, Spain) (68) (Carceller Gonzalez et al., 2007), UCB (Brussels, Belgium) (69) (Raphy et al., 2008), andAbbott (70) (Altenbach et al., 2008; Cowart et al., 2008), Incyte (Wilmington, DE) (74), and academic institutions (Sander et al., 2009; Werner et al., 2010). ZPL-3893787 or formerly PF-3893787 (67) has completed phase I studies and is being developed by Ziarco Pharma (Sandwich, UK) as an oral treatment of atopic dermatitis (Liu, 2014). The other clinical stage compound JNJ-39758979 (72) significantly reduced histamine-induced itch in healthy human subjects (Kollmeier et al., 2014). INCB38579 (74) has demonstrated efficacy in preclinical models of inflammatory pain and pruritus (Shin et al., 2012).

Rotationally constrained analogs of the 2-aminopyrimidine class, including benzofuropyrimidines and benzothienopyrimidines, have also been shown to be potent H$_4$ receptor antagonists. These compounds have been claimed by Argenta (Harlow, UK), Cellzome (Heidelberg, Germany) (Reid et al., 2007a,b,c), Johnson & Johnson (71) (Chavez et al., 2008), and Abbott (73) (Altenbach et al., 2008). Compound A-943931 (73) has shown efficacy in various animal models of pain, inflammation, and pruritus (Cowart et al., 2008).

JNJ-7777120 (58) has been broadly used as standard H$_4$ receptor antagonist to delineate specific pathophysiological functions of the H$_4$ receptor. In fact, JNJ-7777120 exhibits an excellent selectivity for the H$_4$ receptor relative to the H$_1$ receptor, H$_2$ receptor and H$_3$ receptor and numerous other GPCRs (Jablonski et al., 2003). Most animal studies with JNJ-7777120 are compatible with the notion that the H$_4$ receptor
play a proinflammatory role in bronchial asthma, atopic dermatitis, and pruritus and that H₄ receptor antagonism blocks those proinflammatory effects (Dunford et al., 2006; Deml et al., 2009; Rossbach et al., 2009).

However, the pharmacology of H₄ receptor ligands is not clear cut and well understood and therefore care must be taken when interpreting the results from any single ligand. For example, Schnell et al. (2011) reconstituted H₄ receptor species orthologs from human, rat, mouse, and canine with the G protein heterotrimer $G_{\alpha_2 \beta_1 \gamma_2}$ plus the regulator of G protein signaling RGS19 in Sf9 insect cell membranes and measured high-affinity steady-state GTPase activity as a parameter for receptor activation. At all four H₄ receptor species orthologs, histamine acted as full agonist. At human H₄ receptor, JNJ-7777120 exhibited partial inverse agonistic activity, whereas at the other H₄ receptor species orthologs, JNJ-7777120 exhibited partial agonistic activity. Moreover, at canine H₄ receptor, thioperamide displayed weak partial agonism, whereas at human H₄ receptor, the compound was a strong inverse agonist, and at rat and mouse H₄

Fig. 15. H₄ receptor ligands.
receptor, thioperamide is a neutral antagonist or very weak inverse agonist. To make matters more complicated, Rosethorne and Charlton (2011) expressed the human H4 receptor in an osteosarcoma cell line and found that with respect to \( ^{[35}S\)GTP\(\gamma\)S binding, JNJ-7777120 behaved as a neutral antagonist or very weak inverse agonist. In marked contrast, with respect to translocation of beta-arrestin to the plasma membrane, JNJ-7777120 exhibited strong partial agonistic activity. Moreover, JNJ-7777120 induced a delayed activation of the mitogen-activated protein kinase pathway that is typical for \(\beta\)-arrestin-mediated signal transduction (Luttrell and Gesty-Palmer, 2010).

The reported biased H4 receptor signaling by JNJ-7777120 has in the meantime been extended to a broader range of benzimidazole analogs (Nijmeijer et al., 2012), but testing a variety of known H4 receptor ligands has resulted in the identification of biased ligands for both the G protein and \(\beta\)-arrestin pathways (Nijmeijer et al., 2012).

Although data such as these are currently restricted to transfected cell systems and have not been observed in primary cells, it points to the potential complex pharmacology of the H4 receptor and JNJ-7777120. As with any single ligand, researchers must use a combination of tools including agonist/antagonist pairs, ligands from different chemical classes, and/or knockout animals before making conclusions about the function of the receptor.

Discrepancies are also reported in vivo and in primary cells. In a murine model of allergic asthma, the effects of the H4 receptor antagonist JNJ-7777120, the H3 receptor antagonist JNJ-5207852, and the H3 receptor and H4 receptor antagonist thioperamide were compared when given during the sensitization phase in ovalbumin-induced allergic asthma (Neumann et al., 2013). After provocation, JNJ-7777120 resulted in reduced serum titers of ovalbumin-specific IgE, inflammatory infiltrations in the lungs, and eosinophils in the bronchoalveolar lavage as previously reported (Dunford et al., 2006). Thioperamide did not completely mimic the results seen with JNJ-7777120 because it only resulted in lower eosinophil counts in the bronchoalveolar lavage; JNJ-5207852 had no effect on the investigated parameters. The apparent disconnect between the results seen with JNJ-7777120 and thioperamide led the authors speculate that JNJ-7777120 could have effects other than blocking the H4 receptor. However, these differences can also be accounted for by the known nonspecific activity of thioperamide (such as dual H3 receptor/H4 receptor antagonism) or differences in pharmacokinetics. In monocytes as native human cells, a study compared the ability of different H4 receptor agonists (4-methylhistamine [14], UR-PI376, clobenpropit [41], VUF8430, and ST-1006 [75]) in their ability to suppress IFN\(\gamma\) + LPS-induced IL-12 production (Gschwandtner et al., 2013). All agonists had considerable lower potencies in this assay compared with published data from transfected cell lines, and the effect could be only partially blocked by JNJ-7777120 in the case of 4-methylhistamine, UR-PI376, clobenpropit, and VUF8430 but completely blocked the ST-1006 effect. Finally, a study compared the development of murine autoimmune encephalomyelitis in histidine-decarboxylase knockout mice lacking histamine and knockout mice lacking all four known histamine receptors (Saligrama et al., 2013). Whereas the encephalomyelitis was aggravated in histidine-decarboxylase knockout mice, symptoms were alleviated in H1 receptor–H4 receptor knockout mice. The authors speculated that there might be histamine signaling pathways independent of the known H1 receptor–H4 receptor.

**F. Clinical Potential**

Since its discovery at the turn of the millennium the therapeutic utility of targeting the H4 receptor has been a subject of intense research. It is remarkable that in such a short period of time compounds are already entering clinical development. This has culminated with the first clinical efficacy results being published in 2014.

Effects of H4 receptor ligand on pruritus have been among the first studied clinically. Histamine has long been known as a mediator that induces itch in normal human skin, and this pruritic response was shown to be further enhanced in patients with atopic dermatitis (Ikoma et al., 2003). In a mouse model of experimental pruritus, it was shown that both histamine and 4-methylhistamine (17) produced significantly less scratching in H4 receptor knockout mice when compared with wild-type animals (Dunford et al., 2007). In the same study, the histamine-induced pruritic response in wild-type mice was significantly reduced after oral treatment with the selective H4 receptor antagonist JNJ-7777120 (58). Administration of an H2 receptor antagonist, an H3 receptor antagonist, or the peripherally restricted H1 receptor antagonist fexofenadine (13) produced no reduction in the scratching response. Interestingly, the CNS-penetrant H1 receptor antagonist diphenhydramine (6) demonstrated some antipruritic activity, and the combination of diphenhydramine and JNJ-7777120 resulted in the total ablation of the histamine-induced pruritic response (Dunford et al., 2007).

The antipruritic property of H4 receptor antagonism in animal models appears to be broad based. Significant reduction in the pruritic response by JNJ-7777120 has been observed after challenges with allergen and compound 48/80 (Dunford et al., 2007), substance P (Yamaura et al., 2009), the haptens 2,4-dinitrochlorobenzene and tolune-2,4-diisocyanate (Rossbach et al., 2009), and fluorescein isothiocyanate (Cowden et al., 2010). There is also increasing human evidence, including expression of the H4 receptor on skin mast cells...
imply that histamine is not important in asthma, this
indications for H4 receptor ligands. Histamine has long
rhinitis, have also been suggested to be potential
dermatitis and psoriasis.
activity of many cell types implicated in atopic
receptor has been shown to mediate inflammatory
2012; Thurmond et al., 2014a). In addition, the
dermatitis models (Cowden et al., 2010b; Seike et al., 2010)
indicate that compounds targeting the receptor should
be beneficial in a number of pruritic conditions, such as
atopic dermatitis and urticaria.
The preclinical findings have now been validated in
the clinic using JNJ-39758979 (72), a potent and
selective H4 receptor antagonist (Thurmond et al.,
2014a). This compound showed excellent preclinical
safety in rat and monkey 6-month toxicity studies, and
an oral formulation was well tolerated, with the
exception of nausea, in a phase I clinical study with
healthy volunteers (Thurmond et al., 2014a). In a double-
blind study the effect of a single dose of JNJ-39758979
(72), cetirizine (11), or placebo was tested on histamine-
induced itch, wheal, and flare reactions. JNJ-39758979
significantly reduced itching but did not affect wheal and
flare reactions, whereas cetirizine reduced both itch and
wheal and flare (Kollmeier et al., 2014).
This clinical result points to therapeutic potential in
pruritic conditions known to be mediated by histamine
such as acute urticaria, allergic rhinitis, and allergic
conjunctivitis. Furthermore, the combination of the
human and preclinical data supports the potential in
other pruritic conditions such as atopic dermatitis and
psoriasis.
The clinical effects on histamine-induced pruritus
along with preclinical data showing a role of for the H4
receptor in inflammation suggest that inflammatory
skin disease may be attractive indications for ligands
of the receptor. Preclinical data have shown that
antagonism of the receptor is efficacious in several
dermatitis models (Cowden et al., 2010b; Seike et al.,
2010; Matsushita et al., 2012; Ohsawa and Hirasawa,
2012; Thurmond et al., 2014a). In addition, the
receptor has been shown to mediate inflammatory
activity of many cell types implicated in atopic
dermatitis and psoriasis.
Allergic airway diseases, such as asthma and allergic
rhinitis, have also been suggested to be potential
indications for H4 receptor ligands. Histamine has long
been documented to be released in the human lung
during an asthmatic response (Casale et al., 1987).
However, H1 receptor antagonists are only weakly
efficacious in treating this inflammatory airway disease
(Simons, 1999; Thurmond et al., 2008), and there is little
evidence supporting a clinical benefit with H2 receptor or
H3 receptor antagonists. Although the lack of effect may
imply that histamine is not important in asthma, this
seems unlikely given its bronchoconstrictive and proin-
flammatory actions. Instead the lack of efficacy of H1
receptor antagonists may indicate the involvement of
another histamine receptor. Certainly the expression of
the H4 receptor on immune cell types known to be
involved in asthma (such as eosinophils, mast cells,
T lymphocytes, and dendritic cells), coupled with its
involvement in inflammatory processes including chemotaxis
and cytokine production, support the concept that
targeting this receptor may provide therapeutic benefits.
In addition to data derived from cellular expression
and in vitro functional studies, results obtained from
animal models have provided further evidence to support
a role for the H4 receptor in modulating airway in-
flammation. After allergen challenge of sensitized H4
receptor KO mice, there was a significant decrease in
infiltrating lung eosinophils and lymphocytes compared
with sensitized wild-type animals (Dunford et al., 2006).
Ex vivo restimulation of T lymphocytes from the H4-
deficient animals showed significant decreases in a range
of proinflammatory cytokines and indicated that the
receptor was mediating Th2 responses in this model
(Dunford et al., 2006). This dampening of airway
inflammation has also been observed after the adminis-
tration of H4 receptor antagonists in a number of animal
models (Dunford et al., 2006; Deml et al., 2009; Cowden
et al., 2010a; Thurmond et al., 2014a). In addition to the
anti-inflammatory effects in the lung, JNJ-7777120 was
also shown to improve lung function in these mouse
models (Cowden et al., 2010a). In contrast, intratracheal
administration of the H4 receptor agonist 4-methylhista-
mamine was found to be protective in a mouse model of
allergic asthma, potentially through recruitment of
regulatory T lymphocytes (Morgan et al., 2007). However,
the 4-methylhistamine data are difficult to interpret,
because in addition to its agonist effects on the H4
receptor, 4-methylhistamine (17) also exhibits agonist
effects on the H2 receptor (Black et al., 1972). Although
H1 receptor antagonists per se do not play a role in
bronchial asthma, it is possible that there are effects
when combined with H4 receptor antagonists. Specifi-
cally, when applied alone in the sensitization phase, the
H1 receptor antagonist mepyramine exhibited no beneficial
effect on eosinophilia in the bronchoalveolar lavage
fluid in a mouse asthma model (Deml et al., 2009).
However, mepyramine (8) potentiated the therapeutic
effects of JNJ-7777120 (58) in this disease model.
Based on these data, the development of dual H1
receptor/H4 receptor antagonists may be desirable. But
again and by analogy to the data with 4-methylhistamine
(Morgan et al., 2007), the situation may be more complex,
particularly when applied during the provocation phase,
because mepyramine (8) antagonized the effects of JNJ-
7777120 (Beermann et al., 2012a).
The H4 receptor may also play a role in mediating
upper airway inflammation. In patients with chronic
rhinosinusitis, there is a significant increase in the
level of H$_4$ receptor expression in nasal polyp tissue when compared with normal nasal mucosal tissue (Jokuti et al., 2007). In a mouse model of allergic rhinitis, JNJ-7777120 (58) was effective in significantly reducing various upper airway inflammatory symptoms, including sneezing and nasal rubbing, when the compound was given either orally or intranasally (Takahashi et al., 2009). Clinical studies in asthma and allergic rhinitis have been reported for the H$_4$ receptor antagonist JNJ-39758979 (72), UR-63325, and PF-03893787 (now known as ZPL-3893787 [72]), so the question on whether H$_4$ receptor antagonism would provide therapeutic benefits in inflammatory airway diseases may soon be answered once the data from these studies are published.

In addition to inflammatory diseases, a role for the H$_4$ receptor in nociception was recently suggested. Both JNJ-7777120 (58) and its benzimidazole analog VUF6002 (59) were effective in increasing paw withdrawal latency in a rat model of carrageenan-induced thermal hyperalgesia (Coruzzi et al., 2007). Additional work has shown that this compound was as efficacious as the nonsteroidal anti-inflammatory drug diclofenac in this model (Altenbach et al., 2008). Similar effects have also been shown with other H$_4$ receptor antagonists in this model where once again the maximum effect was similar to diclofenac (Altenbach et al., 2008; Cowart et al., 2008; Liu et al., 2008). The amino-pyrimidine H$_4$ receptor antagonist A-943931 (73) was also effective in the carrageenan model, as well as in a spinal nerve ligation model of neuropathic pain (Altenbach et al., 2008). Effects have also been seen in more chronic models. JNJ-7777120 (58) was efficacious in a subchronic inflammatory pain model induced by complete Freund's adjuvant (Hsieh et al., 2010a). Effects were also seen in a skin incision model of postoperative pain using mechanical allodynia as a readout (Hsieh et al., 2010a). In this case, the highest dose of JNJ-7777120 yielded an effect approaching that of morphine. The compound was also tested in model of osteoarthritis joint pain (Hsieh et al., 2010a). This model uses intra-articular injection of sodium monoiodoacetate, and pain was assessed by the hindlimb grip force. JNJ-7777120 was delivered 20 days after sodium monoiodoacetate injection 30 minutes before the assessment. The compound was efficacious and improved the grip force by 47% compared with a 62% improvement with celecoxib. H$_4$ receptor antagonists have also shown efficacy in models of neuropathic pain. In pain models in rats induced by chronic constriction of the sciatic or spinal nerve, JNJ-7777120 showed a reversal that was better than that observed with gabapentin (Hsieh et al., 2010a). Furthermore, the effect was maintained upon dosing for 8 days, indicating that no tolerance development (Hsieh et al., 2010a). Other H$_4$ receptor antagonists have also shown activity in this model (Cowart et al., 2008). Although the mechanism of action of these antinociceptive effects are not clear, the recent observation of H$_4$ receptor expression in the spinal cord, dorsal root ganglion, and certain regions of the brain may offer an explanation (Strakhova et al., 2009b).

In conclusion, the H$_4$ receptor has emerged as a novel and attractive drug target for a range of disease indications, in particular in disorders associated with inflammation. However, there are still many open questions regarding the function of the receptor. Key among these are the exact expression profile of the receptor and the function, if any, in the nervous system. The recent advancement of H$_4$ receptor compounds into clinical development will undoubtedly aid our understanding of therapeutic utilities in targeting this newest member of the histamine receptor family.

VI. Other Responses to Histamine

A. Histamine-Gated Channels

Ionotropic histamine receptors are common in mollusks and arthropods but have not been unequivocally identified in vertebrates (McCaman and Weinreich, 1985; Gisselmann et al., 2002). The ionotropic histamine receptor in invertebrates is a chloride channel related to the glycine and the GABA$_A$ receptor (Fleck et al., 2012). In vertebrates it may turn out to be a GABA$_A$-type receptor with a particular subunit composition. Among the many sites for allosteric modulators of the GABA$_A$ receptor there may also be a histamine-sensitive example. Saras et al. (2008) reported that histamine can directly open homomultimeric channels composed of GABA$_A$ receptor $\beta$-subunits in which GABA acts as a weak partial agonist in Xenopus oocytes (Fig. 16A). In heteromultimeric channels composed of $\alpha_1$$\beta_2$ or $\alpha_1$$\beta_2$$\gamma_2$-subunits histamine is not an agonist but potentiates the GABA response. These effects have yet to be shown in native neurons.

The axon varicosities of aminergic, including histaminergic, neurons rarely form classic synapses in vertebrates and, apart from nicotinic ACh and 5HT$_3$ receptors, the biogenic amines act on metabotropic receptors. Nevertheless there are indications for histamine-gated chloride channels in hypothalamus (Hatton and Yang, 2001) and thalamus (Lee et al., 2004) on oxytocin neurons in the supraoptic nucleus, such a conductance is blocked by the chloride channel blocker picrotoxin (not the GABA$_A$ antagonist bicuculline) and H$_2$ receptor antagonists, not mediated by a G protein. Stimulation of histamine neurons evokes fast inhibitory postsynaptic potentials (IPSPs) that reverse at the chloride equilibrium (Fig. 16B). Hatton and Yang (2001) suggested an ionotropic action and ruled out GABA release from histaminergic axons. Because histamine neurons express GABA, GABA release could have been responsible for these IPSPs.

GABAergic interneurons in the thalamus are surrounded by histaminergic fibers and histamine evokes an inhibitory chloride conductance mediated by a H$_2$-related receptor but not cyclic AMP (Lee et al., 2004). GABAergic
activity of imidazole compounds (Haas et al., 1973), in particular imidazole-derived H₂R-antagonists (Lakoski et al., 1983), has been described. Unequivocal evidence for histaminergic IPSPs mediated by chloride currents has been obtained in paired recordings from the histaminergic C2 neuron and a follower neuron in Aplysia (McCaman and Weinreich, 1985) (Fig. 17).

B. Allosteric Modulation of N-Methyl-d-Aspartate Receptor

A second-messenger-mediated modulation of ionotropic receptors is common for several transmitters: facilitation of N-methyl-d-aspartate (NMDA) receptors through PKC and a reduction of the Mg²⁺-block have been described as a result of H₁ receptor activation (Payne and Neuman, 1997). However, histamine also directly facilitates NMDA receptors and enhances excitatory transmission (Bekkers, 1993), likely through their polyamine modulatory site (Vorobjev et al., 1993). This action is occluded by spermidine and is pH sensitive (Saybasili et al., 1995; Yanovsky et al., 1995). In a slightly acidified environment (pH, 7.0), but not at pH 7.4, the late NMDA component of extra- and intracellularly registered excitatory postsynaptic potentials in hippocampal slices is enhanced by histamine (Fig. 18). Such shifts in pH occur during intense nervous discharges, e.g., during seizures or after tetanic stimulation, and in hypoxic conditions. The effect is not mediated by any of the known histamine receptors but can be mimicked by the histamine metabolite 1-methyl-histamine and is selective for the GluN2B subunit of the NMDA receptor (Williams, 1994), which plays a central role in synaptic plasticity. The H₃ receptor antagonists clobenpropit and iodophenpropit have been identified as NMDA-antagonists selective for the GluN2B subunit (Hansen et al., 2010). Histamine also potentiates NMDA-induced [³H]noradrenaline release from hippocampal synaptosomes through an allosteric site distinct from the polyamine site (Faucard et al., 2006). An action of the diamine histamine on the polyamine site of the NMDA receptor may have been predicted from the cross-reaction histamine-spermidine, jeopardizing the early attempts to label histaminergic neurons through fluorescence histology that was available for the other biogenic amines (Green, 1964).

VII. Future Perspectives

Histamine pharmacology is as exciting now as it was back in the early 1970s when there was only one histamine receptor. Recent advances in our knowledge and understanding of histamine pharmacology, with the identification of the H₃ and H₄ receptors and their isoforms over the last decade and the solving of the H₁ receptor structure in 2011, bode well for potential new improved “antihistamines” and future clinical exploitation of these newer histamine receptors. The spectrum of physiologic and pathophysiological roles of histamine...
has been expanded profoundly over the last decade, with growing evidence in feeding behaviors, sleep physiology, cognitive function, fear memory, pain physiology for the H3 receptor, and chronic inflammation, autoimmune function, gastrointestinal endocrine and salivary exocrine function, pain and itch biology, diabetic nephropathy, and cancer biology for the H4 receptor.

There is still much to understand. The full therapeutic potential of H3 receptor and H4 receptor ligands is just starting to emerge as clinical trial data are published. Furthermore, being the newest histamine receptor, there are many outstanding questions with regard to the characterization of the H4 receptor. In particular it is still not completely clear as to the full complement of cells that express the receptor and whether the receptor has functions beyond inflammation such as in the central or peripheral nervous systems. In addition there is much left to learn about all four receptors with regard to the physiologic and pharmacological relevance of functional selectivity, constitutive activity, splice variants, and oligomerization of the histamine histamine family. Because numerous receptor (hetero)oligomerizations and receptor crossstalks have been reported, one may speculate on the functional properties of numerous compounds with a combined or multitrargeted profile with in vivo application and its adoptive processes.

Acknowledgments

The authors thank Drs. Chris van de Graaf and Albert Kooistra for the illustrations in Fig. 2 of the H1 receptor overall structure and the binding modes of histamine in the X-ray structure (H1 receptor) or homology models (H2 receptor–H4 receptor) of the four different receptor subtypes (Fig. 3).

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Panula, Chazot, Cowart, Gutzmer, Leurs, Liu, Stark, Thurmond, Haas.

References


170. 118–126.

1227. 359–367.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.

110. 275–278.


Histamine Receptors


J Pharmacol Exp Ther 280:8102–8117.


J Pharmacol Exp Ther 210:1032–1045.

J Pharmacol Exp Ther 321:131–140.

J Pharmacol Exp Ther 305:612–620.

J Pharmacol Exp Ther 305:37–47.

J Pharmacol Exp Ther 305:262–279.

J Pharmacol Exp Ther 305:332–338.

J Pharmacol Exp Ther 305:1044–1050.

J Pharmacol Exp Ther 305:8102–8117.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3199–3205.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.

J Pharmacol Exp Ther 305:3188–3199.


